Podcasts about quintiles

Send us a textIn this episode of the Life Science Success Podcast my guest is Matt Veatch, President & COO and Co-Founder of Navidence, Inc., a SaaS company advancing the use of Computable Operational Definitions for real-world data in clinical trials and evidence generation. With over 30 years of experience in biopharmaceutical and medical device development, Matt brings extensive leadership expertise from roles at Syneos Health, Quintiles, and his own consulting practice.00:00 Introduction to Life Science Success Podcast00:30 Meet Matt Veatch: President and COO of Navidence01:22 Matt's Journey in the Life Science Industry05:49 Entrepreneurial Ventures and Consulting06:54 The Birth of Navidence17:26 Navidence's Mission and Impact27:25 Innovative Projects and Partnerships30:58 Matt's Podcast and Personal Insights35:13 Leadership Advice and Inspirations38:55 Concerns and Future Excitements46:33 Conclusion and Farewell

In today's episode, Sarah goes through her setup of her 2025 Goals/Lists planner, a Hobonichi Weeks she will use for tracking and various collections. Then, she answers additional questions sent in the past month. Topics discussed: - Request for planner shop recs around the world + recommendation of Good Postage in Charlotte, NC - Ways to track continuing education data + resources - Sarah recommends going digital for this using a tool like Apple Notes, OneNote, or Notion - Listener tip: a Taylor Swift-inspired planner!? Meet the Mastermind! https://www.etsy.com/listing/1798413186/the-weekly-mastermind-planner-2025 - Another listener's take on Quintiles - the Sextile system! (6 seasons of the year!) - Planner matchmaking request for a small dated daily planner. Ideas included the Hobonichi A6, Take A Note, Sterling Ink 2025 Daily, Midori Hibino (small but CHUNKY), Leuchtturm Daily in Pocket A6, or dating a Stalogy 365 notebook Episode Sponsors: Jenni Kayne: Check out their amazing gifts, from candles to their iconic sweaters . Visit jennikayne.com; listeners get 15% off your first order when you use code PLANS at checkout. PrepDish: Visit PrepDish.com/plans for your first 2 weeks, FREE. MasterClass: Give the gift of learning this season! Visit masterclass.com/bestlaidplans to learn more and find active discounts! Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode, Sarah shares some listener tips + answers questions that came in through email or text (305-697-7189)! Topics include: - Fun tip for using stickers/etc acquired on vacation - Unique Quintiles use case from Emily (http://pfforphds.com/podcast/) - Discussion of annual planning recommendations (note - for those that want a guided annual planning experience, BLP at Home: Planning 2025 will open for registration in October) - Recs for a family calendar system (note - if you love using a digital calendar display system, let me know!) What we use: EC Whiteboard: https://www.erincondren.com/wall-organization-center Essential Calendar (affiliate link): https://www.theessentialcalendar.com/BESTLAIDPLANS - Planning super long term things (like for 1-2 years down the road) - Studying for a big test - how to create deadlines? Episode Sponsors: Jenni Kayne: The Q&A series is sponsored by Jenni Kayne! Gorgeous apparel and home pieces. Visit jennikayne.com; listeners get 15% off your first order when you use code PLANS at checkout. Green Chef: Go to greenchef.com/classplans for 50% off your first box + 50 FREE Credits with ClassPass! Amazfit: Find awesome health tracking watches and more at www.amazfit.com/PLANS (coupon code will provide 15% off!) or look for Amazfit at your favorite major retailer. PrepDish: Visit PrepDish.com/plans for your first 2 weeks, FREE. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textVid Desai is Chief Information Officer, Office of Digital Transformation (ODT), at the U.S. Food And Drug Administration (FDA), where he sets and leads the agency's Information Technology (IT) strategy, as well as the agency's enterprise IT, data management, and cybersecurity. (https://www.fda.gov/about-fda/fda-organization/vid-desai)The ODT oversees the overall FDA IT spend of close to $1Bn and a staff of around 2,500 employees and contractors. In this capacity, Mr. Desai was recently named to the Forbes CIO Next List 2023 and was the only federal CIO to receive this honor. He was also selected as a WashingtonExec Top Government IT Leaders to watch in 2023, in additional to multiple agency and industry awards. Prior to being named CIO, Mr. Desai served as the FDA's Chief Technology Officer, overseeing day-to-day technology operations as the leader of the Office of Information Management and Information Technology.Mr. Desai is a seasoned, nationally recognized technology leader with over 35 years of experience in the IT field, and healthcare and life sciences industries. He has previous experience working for large pharmaceutical and medical device companies, and clinical research organizations.Prior to joining the FDA in 2019, Mr. Desai held the CIO role at Vyaire Medical, a respiratory medical device company formed from a divestiture from Becton Dickinson. He was CIO at Endochoice, a GI device and services provider, and Lake Region Medical, which was acquired by Greatbach to form Integer, a medical device, outsource manufacturer. His previous experience includes IT leadership roles with large CRO and pharmaceuticals, including Quintiles Transnational, where he served as executive director, Global IT Infrastructure. Prior to Quintiles, Mr. Desai held several leadership positions of increasing responsibility with GlaxoSmithKline. He started his career in IT as a software engineer at Digital Equipment Corporation in Reading, U.K.Mr. Desai holds a Bachelor of Science in Computer Science (first class with honors) from Royal Holloway College, University of London.Important Episode Links FDA's Technology Modernization Action Plan (TMAP) - https://www.fda.gov/media/130883/downloadFDA's Data Modernization Action Plan (DMAP) -https://www.fda.gov/media/143627/download?attachmentFDA's Cybersecurity Modernization Action Planhttps://www.fda.gov/media/163086/download?attachment#VidDesai #ChiefInformationOfficer #OfficeOfDigitalTransformation #FoodAndDrugAdministration #FDA #InformationTechnology #ZeroTrust #ArtificialIntelligence #QuantumComputing #IT #Cybersecurity #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the Show.

Welcome to the March Q&A Episode! Topics discussed: - Recommendations for planning and visioning during a job transition phase? - Organizing the many layers of tasks around a big international move - Follow up: Organizing kids' clothes - some tips from listener Sarah K! - Quintiles - do you divide the year evenly? - Details on morning planning sessions - Listener suggestion: Sunday Basket system (Organize 365) for corralling tasks Episode Sponsors: PrepDish: Check out their new PROTEIN BOOST menus! Visit PrepDish.com/plans for your first two weeks free! Jenni Kayne: Find perfect winter pieces at at jennikayne.com. Use code PLANS at checkout to get 15% off your first order and support the show! CONTACT: Email: sarah.hart.unger@gmail.com Voice questions: https://www.speakpipe.com/bestlaidplans Info on Best Laid Plans at Home: theshubox.com/courses Send me a text or voice memo - (305) 697-7189 Sign up for my newsletter: https://theshubox.com/newsletter YouTube - https://www.youtube.com/@BestLaidPlansVideo Learn more about your ad choices. Visit megaphone.fm/adchoices

About Mike Montello:Mike Montello serves as the Senior Vice President, R&D Digital and Tech at GSK, a pharmaceutical company that ranks among the top ten globally and generates over $36 billion in revenue. Oncology, immunology, respiratory disorders, HIV, and infectious illnesses are its strong therapeutic domains. Mike is a sponsor of multiple aspects of GSK's overall digital transformation, including the company's transition to a product-centric structure, its strategic alliances with IT firms, and its digital training initiatives. Building diverse teams and encouraging inclusive leaders are two things that particularly inspire and excite him personally. He gets his energy from speeding innovation through culture. His other main concern is giving GSK's AI machine learning engineers the best quality data in the safest manner possible.Over his career, Mike has worked to improve healthcare via the use of digital, data, and analytics technologies. Mike held the position of CIO at Quintiles prior to the company's 2018 rebranding as IQVIA. He was in charge of the technological platforms that allowed clinical trials to take place in over 100 nations. Along with leading the product teams that developed the next generation of clinical development data and analytics capabilities, decentralized trial platforms, and supported multiple tech acquisitions, Mike also directed the company's R&D technology strategy following the merger with IMS and Quintiles. In addition to spending several years in IT leadership positions at Shire Pharmaceuticals, Mike spent twelve years working as a management consultant at Accenture, where he developed his basic understanding of biopharmaceuticals and technology. Mike has a mechanical engineering degree and graduated from London Business School with an executive MBA.Things You'll Learn:Every pharmaceutical company needs transformation and acceleration.GSK is using AI to identify patients who are most likely to respond favorably to medicines and vaccines by leveraging appropriate data.In the pharma sector, there is a constant need to accelerate clinical trials, drug discovery, and the commercialization process.Large language models and AI will help us a lot with mundane activities.We have to balance the benefits of AI with making sure we're doing things extremely responsibly.It's less about the technology and more about serving people with that technology.Resources:Connect with and follow Mike Montello on LinkedIn.Follow GSK on LinkedIn and visit their website.

What happens when a veteran HR leader sets out to revolutionize the clinical trial staffing industry? Meet Garrett Walker, founder of Virb, a people-centric clinical trial ecosystem designed to provide top talent for pharma companies and clinical research organizations. In this engaging conversation, we explore Garrett's background, his career journey from working in his father's lab to leading talent management at big-name organizations like Verizon, IBM, and Quintiles, and the challenges he's tackling in the clinical trial staffing world.As the clinical trials industry continues to evolve and expand, so does the talent gap. Garrett shares his insights on the importance of investing in early career professionals to fill critical roles like clinical research associate, statistical programmer, biostatistician, and data manager. We discuss the challenges and value of recruiting and re-badging experienced professionals from pharmaceutical companies and the need to provide on-ramps for those just starting their careers. Plus, we delve into the opportunities presented by remote work, AI, and career changes for these early career professionals.But how do we bridge the gap between certification and job readiness? Enter Virb. We explore the role of Garrett's company in creating a training platform that utilizes spiral learning and AI-based systems to customize training for students, helping to shape a new generation of clinical research professionals. Garrett also shares his passion for historical fiction and its connection to the mindset needed for successful career changes. Don't miss this informative and insightful discussion on the future of the clinical trial staffing industry and the critical role talent management plays in running a successful business.Host David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.

Jason Palasota had always been passionate about improving the quality of clinical research services delivered to patients. He first got his feet wet working on the ground level as a site coordinator for Cetero Research, formerly known as Diabetes and Glandular Research. From there, he began to develop an even deeper respect for the industry and continued to pursue opportunities that would allow him to drive change. After working on the ground level, he was inspired to make an impact and improve the quality of clinical research services delivered to patients. Determined to bring about positive change, Jason worked his way up from proposal development and inside sales roles to external business development positions at Worldwide Clinical Trials, ResearchPoint Global, and IQVIA (formally Quintiles). As Jason gained more experience in this field, he became increasingly aware of significant relationship and communication gaps that existed within the industry. He was determined to bridge these gaps by forming strong partnerships between exceptional clinical research sites and innovative sponsors/CROs. His goal was simple: make a positive difference in people's lives through top-tier healthcare solutions around the world. Clinitiative Health Research was born. This week we discuss the various business development models for sites, why sites might want to consider partnering with a business development vendor, and the incredible significance of relationships in clinical research.  Clinitiative Health Research on Linkedin: https://www.linkedin.com/company/clinitiative/   Clinitiative Health Research on Twitter: https://twitter.com/ClinitiativeHR ,  Clinitiative Health Research on Facebook: https://www.facebook.com/ClinitiativeHealthResearch Learn more about our sponsor, Inato: https://go.inato.com/41YxjXY

Este lunes en un nuevo episodio de Página 13, Iván Valenzuela y Kike Mujica conversaron con Ascanio Cavallo y Cristian Bofill, quienes realizaron un acabado análisis del triunfo del Rechazo en el plebiscito de salida, desglosando datos por quintiles y grupos socioeconómicos. Además entregaron detalles de lo que sería un inminente cambio de gabinete.

Este lunes en un nuevo episodio de Página 13, Iván Valenzuela y Kike Mujica conversaron con Ascanio Cavallo y Cristian Bofill, quienes realizaron un acabado análisis del triunfo del Rechazo en el plebiscito de salida, desglosando datos por quintiles y grupos socioeconómicos. Además entregaron detalles de lo que sería un inminente cambio de gabinete.

Welcome to the Welcome to the Celestial Insights Podcast, the show that brings the stars down to Earth! Each week, astrologer, coach, and intuitive Celeste Brooks of Astrology by Celeste will be your guide.   Join Celeste's Leo New Moon Intention Setting Workshop! Book a private astrology reading or horary consultation. Join the waitlist for the Moon Mastery™ Program. Check out Celeste's blog. Download Celeste's free guide to help understand the transiting Moon! Here's Celeste's Amazon storefront, with recommended books and oracle decks!   You can also follow Astrology by Celeste on Instagram, Facebook, YouTube, TikTok, and Yelp.   *****   Astrology highlights for the week of July 17, 2022:   00:49 – This week's theme is: No time for Circus Monkeys! The three big things to focus on this week: First, the fixed star Procyon is active this week, conjunct to the Sun (25 Cancer). Bernadette Brady likens this to fireworks – it's great to watch but fades. Opportunities may present themselves that you have to grab quickly, so if you're offered an opportunity, consider if it helps to diversify your talents! Also, faulty structures may collapse this week – keep an eye out. This star is also associated with dog bites and hydrophobia (fear of water). Stay cognizant about your surroundings this week, too.   02:34 – Second, we'll have an Aries Last Quarter Moon on the Sabian symbol, "A large disappointed audience." The Cancer Sun opposes Pluto in Capricorn. Pluto's symbol is "A large aviary," and Celeste makes interesting observations about what is happening in Sri Lanka: Is there an increase in dissatisfaction with governments in general? When Pluto is activated, there can also be a feeling of empowerment and a drive to transform – do watch out for emotional reactivity! On the plus side, there can be profound emotional healing. Celeste also reviews the Lunar Phase Families, so consider these dates: mid-April 2020, mid-Jan. 2021, mid-Oct 2021, and mid-July 2022. What stories connect for you? (To learn more about the Sabian symbols, revisit Episode 8, "Sagittarius Full Moon: As the Fog Lifts, Clarity Arrives"!)   06:20 – Third: Leo Season begins on Friday! The Sun is at home in this fixed fire sign, where life renews itself. Consider how you can be the sovereign in your own life. Leo, the lion, is a leader: What are you loyal to? For a song of the season, check out Katy Perry's song Roar! Leo is also about self-expression and confidence. Leo season is also a great time to organize something on a large scale. (It's also an excellent time to join Celeste's Leo New Moon Intention Setting Workshop!)   08:46 – On Sunday, the word of the day is FLOAT. The Pisces Moon invites you to drift and dream. Accept all opportunities snuggling, as it is healing.   10:26 – On Monday, the theme is OPPORTUNITY. The Moon enters Aries at 11:22 am PT. If opportunities present themselves, trust your instincts and take action.   11:50 – Tuesday's focus is IMAGINATION. Stay present for a light bulb moment. Consider the positive use of imagination vs. letting fear, paranoia, or obsession take over.   14:17 – On Wednesday, the word is EXPLOSIVE. The Last Quarter Moon is at 27 Aries at 7:18 am PT. The Moon enters Taurus at 11:22 am PT. Observe the conversations around you. Stay grounded, plan your next steps and keep things simple.   15:35 – On Thursday, the theme is PROGRESS. What we nourish grows. What are you feeding? Are they the right things? Release what is no longer serving you. Today, you may meet people who can help you.   17:11 – On Friday, the focus is GENEROSITY. The Sun enters Leo at 1:06 pm PT. The Moon is in Gemini at 10:10 pm PT. Have a fun evening. Connect and socialize with friends, neighbors, or siblings.   18:22 – On Saturday, the word is EXPANSIVE. Learn something new, enjoy yourself and have a laugh.   19:05 – Thanks for listening to Celestial Insights! To support the podcast and help others find the show, please follow or subscribe wherever you listen, rate it five stars, or write a lovely review! And let Celeste know if you have any "astrology in action" stories at Celeste@astrologybyceleste.com! See you next week!

Refilwe speaks to Trustee at the Progressive Principals Association, Riyaad Najaar on how the school fees and quintiles system works. See omnystudio.com/listener for privacy information.

This week I'm joined by Martin Gouldstone, CBO at Sensyne Health. Martin is a 30-year life-sciences veteran in business development and corporate finance with deep experience in sourcing and closing major strategic collaborations in both the digital health and pharmaceutical industries. He joined Sensyne from Syneos where he was Global SVP Capital Solutions at Syneos One and has held senior positions at BenevolentAI, as Chief Business Officer, BDO as Head of Life Sciences in the UK, Results Healthcare, as a partner and co-lead of its healthcare practice and Quintiles where Martin led M&A in Europe. Get in touch with Martini via email: martin.gouldstone@sensynehealth.com Website: https://www.sensynehealth.com/ Subscribe to Healthtech Pigeon

Mika Newton is the CEO of xCures, a health technology company that has created an AI-supported, clinical study platform for advanced cancer. Mika has more than 20 years of commercial strategy and leadership experience in life sciences, with a focus on novel technologies. Over the last 10 years Mika has concentrated on evidence-based medicine and tools to transform healthcare and clinical development. Before joining xCures Mika was the Chief Commercial Officer of Doctor Evidence, LLC. Prior to Doctor Evidence he was the General Manager of Clinical Development Services at diaDexus, SVP of Client and Market Development at Evidera, VP of Sales and Marketing at Archimedes, and held sales management and sales operations roles at Quintiles, Invitrogen and Tripos.

I am honored to be joined by 83 y/o Jack Welber,  I had the pleasure of meeting Jack during a practice open water swim in Boulder 3 weeks ago.  He was preparing to participate at Sprint Triathlon Nationals in Milwaukee.  He is co-author of Not Dead Yet:  World Triathlon Champions 75+ offer tips for thriving & flourishing in later life, available at Amazon and on Audible Jack graduated from the University of Florida in 1959 with a BA in Economics and a minor in Philosophy. He earned 100% of his college tuition and expenses playing jazz saxophone at college events.  After 2 ½ years of military service, Jack began a career in business where he spent 27 years at Johnson & Johnson in middle and upper management. In 2004 at the age of 66, he formed the executive search firm, Wimbledon Group Inc specializing in recruiting oncologists for the pharmaceutical industry. Clients included Pfizer, Bristol Myers, Quintiles and Johnson & Johnson. Jack's love of sports started with high school basketball and track and continued throughout his adult working life. He ran 5K's, 10K's, half marathons and several full marathons.  Back injuries caused Jack In 2004 to switch to triathlon. He hired a coach and began competing in local events on the west coast of Florida where he lived. Starting in 2012, Jack began competing on a national level and ITU Worlds where he had 7 starts and 3 podium finishes including a win in Rotterdam. With heart felt recognition to his good fortune for genetic inheritance, Jack would humbly like to compete in the 85-89 age group next year in Milwaukee.  

In this episode, Sarah does a deep dive into planning larger chunks of the year, whether are quarters or quintiles. She details the feelings and rituals that generally occur in each Quintile, as well as the use of breaking up the year in this way. This episode is sponsored by interactive online yoga studio Stillness + Movement. You can learn more and sign up for class by going to StillnessAndMovement.com and take your first class for free when you use the code BLP.

This episode's Community Champion Sponsor is Catalyst. To virtually tour Catalyst and claim your space on campus, or host an upcoming event: https://www.catalysthealthtech.com/ (CLICK HERE) --- Driven by a relentless passion for improving patient care via the convergence of biology and technology, our next has dedicated himself to curating global communities that are positively moving industry forward.  Dr. Amir Kalali, Co-Chair of the Decentralized Trials and Research Alliance, and Chairman and Chief Curator of the CNS Summit, joins us to discuss his storied career of leading global drug development and health care services in the neuroscience industry and how his experiences have propelled his passion for convening other industry-leading pioneers to improve patient care.  Join us for this action-packed conversation and call-to-action as we continue to work together to move the healthcare industry forward. Let's go!  Episode Highlights: Dr. Kalali's storied career and globally leading initiatives Why Dr. Kalali has dedicated himself to curating communities to move healthcare forward  How to get involved in Dr. Kalali's initiatives About our Guest:  Dr. Kalali is a physician scientist, recognized globally as a leading innovator at the intersection of life sciences and technology, and a convener of collaborative high impact forums. He is a board director of both private and publicly traded companies, and advises companies in the life sciences and technology sectors, universities and investment groups. Dr. Kalali is the Co-Chair of the Decentralized Trials and Research Alliance (DTRA), Chairman and Chief Curator of the CNS Summit, a forum focused on the future of life sciences, and was the Founding Chairman, and sits on the Executive Committee of the International Society for CNS Drug Development (ISCDD), one of the first independent non-profits to bring together leaders in drug development to collaborate, and on the Executive Committee of the International Society for CNS Clinical Trials and Methodology (ISCTM). He is Professor of Psychiatry at University of California San Diego, Editor of the journal Innovations in Clinical Neuroscience, and the Lead Editor of the book Essential CNS Drug Development., published by Cambridge University Press. He has authored over 250 peer-reviewed publications, and numerous book chapters. He has been involved in initiatives by the Institute of Medicine, as well as the NIH FAST and the NIH NCATS programs. Previously, for almost 20 years, he was the Global Head of the Neuroscience Center of Excellence at Quintiles, now known as IQVIA. In this role, he led the enterprise-wide strategy for neuroscience, encompassing drug development and health care services. He was responsible for numerous successful drug development programs that have led to dozens of approved new treatments for patients. Dr. Kalali regularly speaks at national and international scientific meetings on topics including drug development, clinical trials, innovation, technology, digital medicine, biohacking, and health. Dr. Kalali's contributions have been recognized by life sciences media including The Medicine Maker's Power List and the PharmaVOICE magazine's Inaugural Red Jacket award, recognizing those who have been most lauded by their peers. Links Supporting This Episode: CNS Summit website: https://cnssummit.org/ (CLICK HERE) DTRA website: https://dtra.org/ (CLICK HERE) Dr. Amir Kalali LinkedIn page: https://www.linkedin.com/in/amirkalali/ (CLICK HERE) Dr. Amir Kalali Twitter page: https://twitter.com/akalali (CLICK HERE) Clubhouse handle: @mikebiselli Mike Biselli LinkedIn page: https://www.linkedin.com/in/mikebiselli (CLICK HERE) Mike Biselli Twitter page: https://twitter.com/mikebiselli (CLICK HERE) Visit our website: https://www.passionatepioneers.com/ (CLICK HERE) Subscribe to newsletter: https://forms.gle/PLdcj7ujAGEtunsj6 (CLICK HERE) Guest... Support this podcast

  Mike Schultz is the President of RAIN Group, Director of the RAIN Group Center for Sales Research, and co-author of several Wall Street Journal and Amazon Bestselling sales books.   In this episode, Mike discusses how to leverage consultative selling to build trust with buyers and win sales.    Here are some of the topics covered in this episode: Tips on consultative selling and helping buyers make better decisions How to address your prospect's perception of risk Ways to build your likeability The best time to approach buyers About the Guest: Mike Schultz is the co-author of several books including the Wall Street Journal bestseller Rainmaking Conversations: How to Influence, Persuade, and Sell in Any Situation (Wiley, 2011) and Insight Selling: Surprising Research on What Sales Winners Do Differently (Wiley, 2014). He was named the Top Sales Thought Leader globally in 2011 by Top Sales Awards. Mike and the team at RAIN Group have worked with organizations such as Toyota, Monitor-Deloitte, Harvard Business School, Oracle, Fidelity Investments, Ryder, Quintiles, UL, Navigant Consulting, Hitachi, Lee Hecht Harrison, Lowe's, and hundreds of others to unleash sales performance.   Visit RAINGroup.com — a lot of helpful, free resources (blogs, white papers, guides) to help sellers and sales leaders Check out Mike's Bestseller “Virtual Selling” on Amazon - https://www.amazon.com/Virtual-Selling-Relationships-Differentiate-Remotely-ebook/dp/B088KW33WZ  Questions? Shoot Mike a message on LinkedIn (https://www.linkedin.com/in/mikeschultz50/  or email him at mschultz@raingroup.com   Listen to more episodes of the Outside Sales Talk here and watch the video here!    Start Selling More Today with Badger Maps - The #1 Route Planner for Field Sales See Badger in Action: https://www.badgermapping.com/outside-sales-talk-listener/   If you love the Outside Sales Talk podcast, you'll also love Badger's newsletters!  Our 95,000+ subscribers stay at the top of their game with actionable tips from top sales experts.   Are you in? Subscribe to Badger Maps' newsletters now! 

This episode is about homeopathy. And what healing the entire person really means. Homeopathy was once something I knew nothing about (and I am only brushing the surface right now) and felt pretty random to me, but has since then blown my mind, has changed the way I think about the body, healing, and water. I hope this episode nourishes you as much as it did me. There are so many treasures of healing for us to discover both individually and collectively. Elizabeth is a homeopath who trained with the Irish School of Homeopathy. She obtained her license in 2006 and since then she has had a varied and rich practice, in Ireland in Spain, and online. Now she feels truly inspired as a teacher of homeopathy at the Da a Luz school in the Alpujarras. She wishes to expand teaching and her homeopathic practice to empower as many as possible to truly understand the wonderful bounty of health when it is taken as a personal responsibility on the journey of life. Her practice has been a lot about the family, about healing childhood illness, and the illness of the mind. That said, Elizabeth's homeopathic practice has known no bounds in the conditions treated everything from severe alopecia to infertility, suicidal thoughts to addictions. Her practice has been more about the people than the conditions. The holder of the disease than the disease itself. Usually, her clients are people who are looking to empower themselves and just need to be shown the way. Developing her homeopathic practice she has taken several post-graduate courses with Jeremy Sherr, Anne Walker, Peter Chappell, and Nuala Eising. All of these are inspirational teachers who are breaking new ground for homeopathy. She worked at the Eva Demaya Foundation in Malawi for just under a year, just after graduation. She says that this is when the power of homeopathy became concreted in her mind as the remedies were often the only thing available for serious and advanced conditions. At these critical times, they worked more clearly and brilliantly than ever. She was born in the west of Ireland. Elizabeth is passionate about all things natural, having been raised deep in the countryside, immersed in nature, the wild, and a farm full of animals. Her primary education led her to a degree in Natural Science focused on Biochemistry. Again an immersion to the nature of our being at a cellular level. It was an amazing study. This lead to a Master in Medical systems. In post-graduate years from the science degree, she worked for clinical trials with Quintiles and then subsequently several large pharma and medical device companies like Novartis, Boston Scientific, and Abbotts. These were years where she learned a lot about the materialistic, industrial world and how contrary this is to nature. Only through a love of yoga and an introduction to Homeopathy did she pull herself out of this field of work and to her true joy as a homeopath and teacher. Elizabeth is now a mother of two boys and lives in the Alpujarra, Southern Spain. She continues to work building her teaching and practice of homeopathy. She can be reached through email: elizabethjflynn@gmail.com by telephone (whatsapp and telegram) 0034 603497559 or check out her website (in construction): www.thatlikehealslike.com

Greg teaches the capstone course Sustainable Innovation in Healthcare: Managing Continuous Improvements in Developing Products and Services. He is also Chief Medical and Information Officer at PRA Health Sciences, a leading pharmaceutical service, healthcare data and contract research firm. Previously, he was President and Chief Medical Officer at Castle Creek Pharmaceuticals, President of Rare Disease at Moderna Therapeutics, and had leadership roles at McKinsey & Co., Quintiles, Inc., Proteostasis, Amicus Therapeutics, Domain Associates and Medtronic Neurological. He was co-founder of Immunome Therapeutics. Greg has degrees from Harvard Business School, Yale School of Medicine, Columbia University, and Boston College. He trained at the Brigham and Women's, Children's, and Massachusetts General Hospitals. He is on non-profit advisory boards. Greg writes about innovation for Forbes.

How do you get to be the person in the room, or on the zoom, that catches everybody's attention? Susan Heaton-Wright, creator of the Superstar Communicator methodology, has worked with the CII and global organizations to teach business leaders how to make an impact when communicating. Listen to this fascinating chat with Boston Tullis's Sarah Myerscough to unlock the secrets of influencing via verbal and non-verbal communication.   Quote of the Episode “Do you know listening, I believe is a huge superpower. And we know from face to face meetings, you remember those old days when we have face to face meetings, there was this idea that you need to speak, and you needed to be heard. But actually, one of the most important things if you're in a service industry, is listening, and watching to see how the other person says what they're saying.”   Resources Pole Pole Song: https://youtu.be/tgqAOCtwLOo   About The Guest Susan Heaton-Wright empowers leaders and teams globally to work and communicate virtually and in real life. She has trained attendees from over 50 countries: regions include EMEA, The Americas and South East Asia. Susan delivers masterclasses, virtual workshops, virtual coaching, workshops and individual coaching for many companies including Astra Zeneca, Microsoft, RBS, Deloitte, AAP, Invesco, Shell, AXA and Quintiles. She is regularly interviewed on BBC Radio Five Live; BBC2, local radios and international podcasts. In 2020 she was named in the #ialso 100 top inspirational female entrepreneurs with f:entrepreneur and has contributed to articles in Forbes, The Guardian, Huffington Post, Thrive Global, The Scotsman and trade publications. Connect with Guest –  Susan Heaton-Wright | LinkedIn   About the Host Sarah Myerscough is the Sales and Marketing Director of Boston Tullis Group. The founder of The Insurance Brokers Podcast, she brings a wealth of marketing experience and a fresh perspective on marketing in the insurance sector. Boston Tullis is a network of industry professionals working with insurance brokers to offer solutions to business development ceilings, particularly in the rapidly developing fields of video marketing and thought leadership.   Connect with Sarah - https://www.facebook.com/bostontullis   https://www.linkedin.com/company/bostontullis/ https://www.linkedin.com/in/sarahmyerscough/ https://bostontullis.co.uk/   HOSTED BY: Sarah Myerscough, Sarah.Myerscough@bostontullis.co.uk mobile: 07821903628   DISCLAIMER: The views, thoughts and opinions expressed in this podcast belong solely to the host and guest speakers. Please conduct your own due diligence.

Jupiter Enters Pisces & Quintiles Uranus * Taurus New Moon * Double Yod Key * Free session winner! Click here for complete show notes on AstroShaman.com.Listen to This Week in Astrology now -- free!

You don't have to be loud to stand out as a leader but you do need to have presence. In this episode I talk with Susan Heaton-Wright, about the importance of tone of voice when it comes to executive presence. Susan shares some great insights and tips for introverted women leaders on how to make the most of their voices when wanting to command the room and have presence. About Susan Susan Heaton-Wright is a Virtual impact, communications and speaking expert for emerging leaders and the creator of the Superstar Communicator™ methodology. She is an international speaker; the MD of award winning music company, Viva Live Music, podcaster and a former prize winning international opera singer. In 2020, she was named as an #ialso 100 top inspirational female entrepreneurs in UK. She is a Fellow of the Professional Speaking Association. She delivers virtual seminars, workshops and individual training for many companies including Astra Zeneca, Deloitte, Invesco, RBS, Shell, Microsoft, AXA, the NHS and Quintiles. Her area of expertise is in Impact, Presence and spoken communication. Her virtual courses are CPD accredited independently; she is also a fully qualified teacher. Susan regularly delivers remote speeches and seminars to professional organisations and businesses, as well as leaders and emerging leaders in organisations. She has spoken in Lithuania, France and The Netherlands, as well as throughout UK, at conferences; as a panellist; business events; lunch and learn sessions and trade shows. More recently Susan has been speaking virtually to international audiences, including virtual conferences. She is regularly interviewed on BBC Radio Five Live; BBC2, local radios and international podcasts. Susan has contributed to articles in Forbes, The Guardian, Huffington Post, Thrive Global, The Scotsman and trade publications. Susan is a Fellow of the Royal Geographical Society, The Royal Society of Arts and the Incorporated Society of Musicians. Susan is a former Regional President of PSA UK, for the Eastern Region. She leads a project of musicians in Greece annually, to deliver music workshops to refugees in Athens as part of the ‘Love without Borders' charity. Find out more about Susan at www.superstarcommunicator.com

The Thoughtful Leader with Mindy Gibbins-Klein Episode 007 Communicating for Maximum Impact with Susan Heaton-Wright Thoughtful leaders care about how they come across, how they're perceived, and the impact of their communication.  Susan Heaton-Wright is a thoughtful leader, communication and speaking expert for emerging leaders, corporate leaders and teams, using her Superstar Communicator™ method. Her clients include Astra Zeneca, Deloitte, RBS, Shell, Microsoft, AXA, the NHS and Quintiles. She is also a Fellow of the Professional Speaking Association. Susan's workshops and trainings prepare people for all public speaking experiences, from doing television interviews, to using your voice properly on podcasts. In our conversation, Susan gave some great advice for improving your speaking skills including: Communicating requires paying attention to tone and non-verbal skills. Dealing with the dominate speaker in the room. Overcoming the fear of speaking. Learning the value of other people's voices. Learn to listen to better analyze conversations. Take advantage of Susan's free speaking tips noted in the notes below.  Here's to your Thought Leadership Journey! Connect with Susan: Website: superstarcommunicator.com/ten-top-tips/ Connect with Mindy: URL: https://www.mindygk.com/ Twitter @MindyGK https://twitter.com/mindygk Facebook @mindy.gibbinsklein https://www.facebook.com/mindy.gibbinsklein LinkedIn https://www.linkedin.com/in/mindygibbinsklein/  Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Sarah does a deep dive into planning larger chunks of the year, whether are quarters or quintiles. She details the feelings and rituals that generally occur in each Quintile, as well as the use of breaking up the year in this way. This episode is sponsored by interactive online yoga studio Stillness + Movement. You can learn more and sign up for class by going to StillnessAndMovement.com and take your first class for free when you use the code BLP.

It is always a great pleasure to engage with clinical trial innovator and thought leader Craig Lipset. We asked Craig to join the People Always, Patients Sometimes podcast to share more information about DTRA, which stands for Decentralized Trial and Research Association. As an industry, we have embraced more fully the idea of serving patients better with a decentralized clinical trial. As we bring the corona virus under control, it's important that we don't become complacent and return to business as usual. Give a listen to the podcast and I hope you'll join us in declaring there is no going back.   Janet Kennedy: (00:43) It is always a pleasure to welcome Craig Lipset to the podcast. He is a man that really needs no introduction, but I'm going to give him one anyway. As the former head of clinical innovation and venture partner at Pfizer and on the founding operations committee for TransCelerate Biopharma, Craig is recognized as a leader at the forefront of innovation in clinical research and medicine development. He is a frequent speaker at healthcare and pharmaceutical conferences, and he has also led the call to innovate and recognize that there is #nogoingback to improve clinical trials. Today though, we're talking about DTRA, Decentralized Trials and Research Alliance. Welcome to People Always, Patients Sometimes Craig.   Craig Lipset: (01:29) It is such a pleasure to be back with you, Janet, thank you for everything that you're doing to give so many voices the opportunity to share.   Janet Kennedy: (01:38) Oh my great pleasure. This is always a learning opportunity for me. I am not a journalist, but I do play one on this podcast and I get to ask all the air quotes, dumb questions, that I'm sure a lot of people want to know about, but sometimes they get caught up, that something's already rolling ahead. And they're like, did I miss it? Did I have a fear of missing out what's going on?   Craig Lipset: (02:00) Absolutely. You know, there's so many different ways for people to stay current and stay connected. And you know, sometimes we have to hit a lot of different channels to make sure that everybody gets that opportunity to, to connect and to stay current with what's going on out there.   Janet Kennedy: (02:18) So on the connection aspect, we obviously have been dealing with the pandemic for gosh, a year now, and this time last year we were preparing for the last in-person event, which might've been SCOPE, and then suddenly things spun out of control and we were all sent home. I think things have changed a lot for you as well. So I'm curious, being able to look back a year over how things happened in 2020, what do you think has really impacted clinical trials with folks being sent to their rooms?   Craig Lipset: (02:56) You know, I think a lot of people will expect me to say things telemedicine and remote monitoring and risk-based monitoring. I would say that the thing that's really impacted us is willingness to adopt. And what I mean by that is so many of the things that have been so important for business continuity this year, the things that have kept our trials running weren't solutions that had to be cooked up in a lab in the year 2020. Most of these were solutions that already existed. They were just struggling for adoption, usually struggling for adoption because we operate in a very risk averse environment. But when the risk changed in the environment and all of a sudden, some of these things that might've been viewed as risky, suddenly became risk mitigation, they became the way to maintain business continuity. 2020 became a story about adoption, about so many great solutions that had been at our feet that had been at the doorstep suddenly seeing their moment in the sun when study teams and organizations were able to pick them up and bring them into their studies and bring them into their portfolios. And that's an exciting way for us to now get 2021 going, because now our organizations have seen that we can bring these different things to life, whether it's risk-based monitoring decentralized trials or whatever other solution your listeners were able to bring into their organizations to keep their work going.   Janet Kennedy: (04:23) Well I think that's an interesting point and you've been fortunate in that you've been able to sit a little bit in the cat bird seat because you've had an opportunity to participate in a lot of virtual conferences. You advise a number of companies. So you've been able to get feedback from a lot of different sources, as opposed to, if you were solely ensconced at Pfizer, you might not have access to the kind of information I'm thinking of. So here's my question. Do you believe that all companies, saw that opportunity to innovate and to accept and to accelerate? Or do you see that there's been a, sort of a separation of the wheat from the chaff and there are the companies that already had a innovation growth mindset, and then there are the folks that are just struggling to keep up?   Craig Lipset: (05:11) I think that in that April, May, June timeframe, a lot of organizations were all in the same boat. They were all trying to scramble to keep their portfolio going. They were rushing to introduce whatever countermeasures they could to keep patients being monitored, keep drug supply flowing, and keep capturing data. So that studies didn't wind up futile. But, Janet, I do think that we start to see some separation when we look to the latter half of 2020, because in that latter half of 2020, then we start to see that there are some sponsors out there that are starting to commit to some of these changes they're putting in place, new resources, they're relooking at some of their SOP and processes. They're expanding their vendor and partner lists some really starting to rethink how they write protocols and introduce some new training. These are the companies that are really starting to show commitment. They're really looking at the things that were adopted earlier in the year and being thoughtful about what's needed now to instantiate these and make them a part of our organization going forward. And that's different from some others that just maybe haven't been able to step forward to make those kinds of organizational commitments yet because they're hard.   Janet Kennedy: (06:35) Well, not only, they're hard; you may not even have the environment within your company that can embrace that kind of change and thought process. You really do need leadership that is willing to invest in that kind of information and that kind of structure, those kinds of individuals.   Craig Lipset: (06:53) Absolutely right, Janet. If there's one thing we saw in 2020, it's that these new approaches, well, they don't need special regulatory permission. Yes. The FDA produced some really important guidance for the industry about running clinical trials during the pandemic. But I encourage people to take a close look at that guidance. They didn't lower the bar on what technologies or approaches to introduce. They just said, use them and use them thoughtfully engage with your regulatory reviewers. And so from a regulatory perspective, these solutions were available; from a technical perspective, they were available. What does that leave? Exactly where you're pointing - culture, and our organizations ready in terms of their own internal culture and receptivity and willingness to change, or is it the culture that will ultimately stand in the way of those organizations being able to commit to and adopt these new approaches that were introduced last year?   Janet Kennedy: (07:51) I imagine that's a big part of what you do as a consultant is helping companies revision how they look at the growth of their company and expanding their capabilities through innovation.   Craig Lipset: (08:04) You know, Janet, I can only help organizations that are ready to be helped, but when they call, I'm certainly happy to be there. And mostly what I do professionally, whether with pharma companies, tech companies, or with others, is to help them make their strategies fabulous. And to help them make their implementations resilient. I can't fix the culture on my own. I can't show people solutions that they're not ready for. And so, you know, I can really only come in if leaders are ready to commit to these areas.   Janet Kennedy: (08:39) So you had a lot of time on your hands where you might've been traveling on airplanes, going places, and you obviously found a nice little hobby on the side where you decided to get together with some other thought leaders and launch a new initiative, the DTRA, the Decentralized Trials and Research Alliance. So I'd love to know the backstory. How did that come about?   Craig Lipset: (09:04) With all of that free time? Really Janet. So, it's interesting. DTRA is planning actually preceded the pandemic. It dates back to just prior to the pandemic when a friend and colleague Amir Kalali, who is well known in the industry from his time at Quintiles leading the neurosciences, and his time as the leader for the CNS summit Amir reached out and that he was exploring some different convening opportunities around decentralized. And we both appreciated that the world didn't need another conference on this topic. But when we have talked about decentralized in different meetings and events, there was always something left on the table. There was something that would come up at every one of those conversations about an opportunity to make the field better together. That was then left behind when that conference ended. And so we started to explore together what could be really sustaining and help to change this field.   Craig Lipset: (10:02) And then, the pandemic emerged. Which, in many ways, amplified everyone's attention around decentralized, but also was pretty distracting in terms of people needing to be heads down and keeping their portfolio going. And so while there was a lot of interest from a lot of my network around coming together with the DTRA, we did have to push some of our plans out to later in the year and give people in their organizations time to make the adjustments that they needed to, internally. By the end of 2020, in early December, we were ready to go live. And so made a public launch of DTRA, the Decentralized Trials and Research Alliance. We had over 50 founding organizations as members. These were groups that really took a chance with us believing that there would be a community that came together to try to make adoption of decentralized research, easier and help drive the scale that we know as possible, but it's hard.   Craig Lipset: (11:04) And so with that, we launched DTRA. Now we're at about 85 members. I think we'll probably be at a hundred member organizations and over the next month or so, we keep posting those updates on LinkedIn and Twitter. So what is DTRA? There's really two aspects to the decentralized trials research Alliance that I speak to. One is the work that we're doing together. The initiatives that we're taking on, and the second is the network and the community that we're creating that can support B2B transactions and raising more awareness and activity in the field. For the initiatives, our leadership council, our members, defined four priority areas together. The first is around definitions and how we agree on archetypes and key performance indicators to help reduce some of the tower of Babel in this category and help make sure that we're talking about the same things in our conversations with one another.   Craig Lipset: (12:06) The second area has been around best practices considering that our members, whether pharma, whether CROs, tech companies, site networks, advocacy groups, and the FDA themselves, our members have been involved in most all of the decentralized research studies that have gone out in the last few years. What are the learnings, the best practices that we can identify together to help make implementation easier? The third area for us is themed around education, because so many of us get stuck needing to bring our organizations along or other stakeholders, like investigator sites or patients and their caregivers. What type of educational resources can we begin to aggregate and share, and in particular, use data and evidence to drive that education? As an example, we all talk with enthusiasm about the potential for decentralized research to improve diversity in clinical trials. But where's the data and the evidence to back that up?   Craig Lipset: (13:10) We believe that by having a multi-stakeholder initiative in a nonprofit space like this, we'll have the opportunity to gather the data and evidence across our members. A fourth area, the fourth priority for us is around removing the remaining obstacles that stand in the way to meaningful adoption. And so those might start to include topics like interstate licensing or global regulatory variability, or other priorities. that our members are working together right now to identify and prioritize. Now I know firsthand from my time at Pfizer that we are not the only initiative collaboration consortia operating in this environment. And in fact, we have identified and begun to engage with over a dozen different initiatives, consortia, collaborations that cover a number of different topics, but might have a work stream, a taskforce, a work group that's looking at decentralized trials together and trying to solve a specific problem.   Craig Lipset: (14:12) We've begun to reach out to each one of those organizations and have been really well received in our call for transparency and collaboration. And by that, what we're looking to do is pull together the overall roadmap across the different collaborations in this space, because when it comes to decentralized trials, it's the only thing DTRA cares about. It is our sole priority. And so we're very well positioned to help show our members and others what different work is already happening here. Make sure there's no redundancy. Make sure that there are handoffs when it makes sense. And Janet, I mentioned earlier that there are really these two areas; one around our initiatives, and the second is a bit the leans in more around network. We realized that our members are the buyers, the sellers, the implementers of decentralized research. Our initiatives are very specifically a non-selling zone there to get work done together.   Craig Lipset: (15:09) But people in our community want to know about the capabilities of one another. It might spark business to business collaboration among different tech companies or tech and service providers or opportunities to engage with sponsors that might not have otherwise known of certain capabilities. We're also starting to explore opportunities to help some of the younger companies in this category with access to capital, and what ways we can create showcases for investors that are very interested today in decentralized research, and make sure that the spotlight is shown on those that are growing new capabilities here. And so whether for these initiatives or for these network opportunities, or a little bit of both, that seems to be what's drawing this community together.   Janet Kennedy: (15:53) Gosh, have you said this before?   Craig Lipset: (16:00) Maybe in my sleep. I'm sure my kids are sitting in the other room saying, "Really dad? Again?"   Janet Kennedy: (16:07) Okay. So I have a couple questions. I'm curious about the membership. You said you're hoping to grow to about 85 to a hundred members and maybe beyond that, but that sounds like it's all pretty corporate members. Is there an opportunity for individuals to engage in this?   Craig Lipset: (16:25) That is a fabulous question, Janet. And right now our members are organizations. They can be corporations, they can be nonprofits. We have a number of advocacy groups, and obviously we have the FDA and our opening engagements with other regulatory agencies. The idea of individual members is something that our leadership and our board have been very actively exploring. Individuals might be between gigs. They might be independent contractors. Maybe they're just great advocates for this field, that want to grow their career in this direction, but their current employer isn't a member because it doesn't align to their employer's goals. We are finding ways to engage with these individuals. Today, those might be roles that are based a little bit on sweat equity, where some individuals want to step forward and help to manage and lead some of our initiatives and work streams. Going forward, though, we are going to be looking later this year for other ways, to open our doors for individual members. And so I would encourage those who are individuals whose organizations might not be members today to visit dtra.org and click to sign up for more information, so that you'll be on our email list. And as new opportunities emerge, you'll be right there among the first to see them.   Janet Kennedy: (17:47) Obviously just the concept, a decentralized trial, I would assume, that its foundation is 'because that's what's best for the patient'. How are patient advocates and the patient experience part of the DTRA planning?   Craig Lipset: (18:04) While in 2020, a lot of implementation had to be rushed to try to salvage and maintain studies, in general, our clinical research community is eyes wide open today to actively including patient input and insight from day zero of the earliest plans, whether for a protocol, or if they're smart, for a new technology they're looking to implement. And so for that reason, we wanted to make sure from the very beginning patient voices were an active part of our community. Two of our earliest member organizations, the FasterCures TRAIN Network and the Genetic Alliance joined in many ways, because they're not representing a single disease, but represent a community of different disease specific advocacy groups. And so in each of those instances, while that is a seat of one organization, that one organization is disease agnostic and includes constituents across a broad range of different therapeutic areas. Now, as more patient groups have been reaching in, many of them are actively offering to help serve as a channel for patient input and insights as DTRA initiatives and other priorities start to identify, be they educational needs or other areas to go after. I think we're developing a very nice stakeholder base of patient groups that will be there by our side and help to serve as a fresh channel for getting patient input into our work.   Janet Kennedy: (19:36) Is there a concern at all that if this is primarily fueled by and funded by for-profit organizations, even though DTRA is a nonprofit organization, that there might be an imbalance of the size of the voice?   Craig Lipset: (19:53) It's a very fair question. Right now, every organization, whether for profit, nonprofit, whether service provider, tech provider, sponsor or otherwise, every member has one seat in one voice in our leadership council. But to your point, we do want to maintain fairness and equity and the different voices that are out there. I think that we have enough active leaders in this organization that are keenly aware of thoughtful of, and sensitive to patient voice today, that well, shall I say in most cases when the patient voice is raised, most people are smart enough to take a step back and make sure that voice is being heard. And if they don't, they're probably going to hear about that from their peers today.   Janet Kennedy: (20:41) Excellent. I am curious about how does a company, a member actually engage? Are you having monthly zoom calls? Are you actually working via email? How do you plan and implement some of the programs that you're doing?   Craig Lipset: (20:59) Every member organization has a seat on our leadership council, which has a quarterly business meeting. In these business meetings where we're reviewing the status of the various initiatives and other work that may be happening. We also have a quarterly community meeting for that leadership council. This is a bit softer. It's not covering the hard topics such as what initiatives progress and status is looking like. But in contrast, these are a bit softer topics that our members have flagged to us as being important to them. One great example there is exactly where you started this conversation, Janet, around culture. Are there tactics that different organizations have been able to introduce in their organizations, large or small, that have been particularly successful or unsuccessful that we can use this community to help share and propagate with others? As I mentioned, in addition to our leadership council, we do have several initiatives that are underway and those initiatives will meet much more frequently. As they get going, they're meeting weekly. And as they get moving that cadence may back off a bit. But right now we're very much in the prioritization stage. It's a pretty busy time right now, as these initiatives are getting going. And so the cadence is a bit busier than it probably will be as we move into more of a steady state.   Janet Kennedy: (22:26) So the pandemic has gone on long enough and will continue to go on long enough that anybody who was hoping to wait it out, I'm sure has learned that, to their detriment, that they were slow off the starting blocks. I assume now it's sort of full steam ahead for the concept of decentralized trials, or are you still feeling that there are folks hoping that the good old days will be back again?   Craig Lipset: (22:53) You know, Janet, I think that our community is like any other and we have a distribution of individuals. I think that we have individuals in all of our organizations at the far right of the adoption spectrum; they want to be the first, they want to embrace the new. I think then we have a bolus of colleagues that are receptive to doing the new, if it feels safe, and if it feels supported. we have others that may be a little more indifferent. And then we'll always have that tail of the other end of the continuum who are very comfortable that really don't want their cheese moved, and well, to be honest, are perhaps most likely to trade out, given how dynamic and how much change occurs in all of our organizations every year. You know, I often think about, Janet, the Ted Talk with the video of the dancing man.   Craig Lipset: (23:45) And if folks in your audience haven't seen this one after the podcast, they should go Google this one up because it's a great voiceover of a story of a concert taking place on a hill. And in this video, you start off with a bunch of people that are listening to the music, sitting on their picnic blankets. And then there's a guy who just gets up and starts dancing. Well people are looking at this guy, and he's the only one standing there dancing. And you know what you're probably thinking - he's looking like a nut. But after that, there are two or three other people that start to get up and dance. Once they do, it validates for everyone else on the hill. Now it's not just a story of one nut dancing by himself, but it's a story of a small crowd that is much safer. And once that happens, it's that rapid tipping point. Everyone else on the hill is now off their picnic blankets and up and dancing. And so I think about it that way with so much of our change in this space. There'll be some people that don't want to get up and dance ever, but once it's made to feel safe, once there's just a couple that are getting up and making it happen, the rest of our community does step forward. They will be up there dancing as well.   Janet Kennedy: (25:04) Well, on behalf of a dancing man representative, I believe that that is an exciting place to be - out there, by yourself, trying, doing what feels right, feeling that emotion of just doing the thing that really is right for you. And when other people join you, that just makes it that much sweeter.   Craig Lipset: (25:29) Sometimes it takes time. Sometimes you might feel like you're out there dancing for a while, but I totally agree with you, Janet. We are so fortunate to work in this industry. Our community does amazing work, developing medicines for patients with unmet medical needs. But even within this space, we know there's so much more we can do. And we know that there are things that we can do just because they are the right things to do. And so a lot of us do, you know, get up and dance and take that chance. And sometimes it takes a little while, but if you're doing the right thing, others will get up and dance with you. It just may take a little time.   Janet Kennedy: (26:07) Absolutely. Well, I would love to get more people involved in DTRA and also following the news that you're going to be sharing. So tell folks a little bit about how to find out more about Decentralized Trials and Research Alliance.   Craig Lipset: (26:22) Three ways for folks to do that. For those who are social, the first two ways are LinkedIn and Twitter. We're really committed to keeping content flowing, to helping to serve as a trusted news and resource for folks on LinkedIn and Twitter about activity in the decentralized trial space. And then finally, check out dtra.org. If you're interested in learning more, either about organizations participating or just yourself staying current, go ahead and sign up there to stay connected with DTRA.   Janet Kennedy: (26:55) Thank you so much for sharing that, Craig. I had a lot of questions and you were very patient about answering all of them.   Craig Lipset: (27:02) You're fabulous Janet. Thank you, and thanks to your audience for spending some time this day.   Janet Kennedy: (27:07) So if you want to find the link to the dancing man video, or of course, a lot more information about DTRA, please go to spencerhealthsolutions.com and you will find the post of this podcast on our website, under podcast. And we'll have all the links there as well as the links to find Craig in social media as well. Craig, thank you so much for joining People Always, Patients Sometimes.

In this special episode of The Career Success Podcast we speak to communications expert Susan Heaton-Wright, on “Lawyers, how to sell yourself and communicate well”Susan Heaton-Wright is a Virtual impact, communications and speaking expert for emerging leaders and the creator of the Superstar Communicator™ methodology. She is an international speaker; the MD of award winning music company, Viva Live Music, podcaster and a former prize winning international opera singer.She delivers virtual seminars, workshops and individual training for many companies including Astra Zeneca, Deloitte, RBS,  Shell, Microsoft,  AXA, the NHS and Quintiles. Susan is regularly in the media, having recently appeared in The Guardian, Huffington post, BBC news and ITV news.

In today’s episode, Chad sits down with guest Mike Mortimer, co-founder, and partner of London-based GHO Capital. Mike has had a distinguished career in healthcare including senior leadership roles at Quintiles, board positions with numerous healthcare companies including BioAgilitx, and for the last six years with GHO Capitals. At Quintiles he was a part of the team that grew the company to be the dominant late-stage CRO in the industry and now at GHO Capital, his team directs funding to build the future of healthcare with a focus on European investments. They chat about the business side of the pharmaceutical industry, his thoughts on Brexit, and biking over 2,000 miles! See omnystudio.com/listener for privacy information.

Welcome to Episode 263 of the Yeukai Business Show. In this episode, Susan Heaton-Wright and I discuss how to gain inner confidence with public speaking. So if you're one of those people who are very talented, but feel you're lacking in communication skills and want to overcome your weaknesses so you can unlock new career opportunities, tune in now! In this episode, you'll discover: Where to start with developing confidence 5 key areas in channelling your inner communication superstar Effective ways to manage your nerves Overcoming the fear of public speaking About Susan Susan Heaton-Wright is an expert a communication superstar  whose accomplishments include: A Virtual impact, communications and speaking expert for emerging leaders globally.She empowers talented people to create impactful business conversations.She is the creator of the Superstar Communicator™ methodology: a 5 step system for speaking and communicating effectively.Susan is the MD of award-winning music company, Viva Live Music, podcaster and a former prize-winning international opera singer.She delivers virtual seminars, workshops and individual training for many companies including Astra Zeneca, Deloitte, RBS,  Shell, Microsoft, AAP, Invesco,  AXA, the NHS and Quintiles.She is delivering virtual workshops, masterclasses and coaching globally to leaders and emerging leaders. Many of her clients go on to be interviewed on Sky News and BBC as well as speaking at industry conferences. She is regularly interviewed on BBC Radio Five Live; BBC2, local radios and international podcasts. Susan has contributed to articles in Forbes, The Guardian, Huffington Post, Thrive Global, The Scotsman and trade publications. In 2020, she was named as an #ialso 100 top inspirational female entrepreneurs in UK.Susan is a Fellow of the Royal Geographical Society, The Royal Society of Arts and the Incorporated Society of Musicians. She leads a project of musicians in Greece annually, to deliver music workshops to refugees in Athens as part of the ‘Love without Borders’ charity. More Information Learn more about how you can improve your results with public speaking: Superstar Communicator Website Superstar Comms Twitter  Facebook LinkedIn  Links & Mentions From This Episode: Susan’s podcast is Superstar Communicator which has been named a top 20 Communications podcast in the USA. Thanks for Tuning In! Thanks so much for being with us this week. Have some feedback you'd like to share? Please leave a note in the comments section below! If you enjoyed this episode on how to gain inner confidence with public speaking, please share it with your friends by using the social media buttons you see at the bottom of the post. Don't forget to subscribe to the show on iTunes to get automatic episode updates for our "Yeukai Business Show!" And, finally, please take a minute to leave us an honest review and rating on iTunes. They really help us out when it comes to the ranking of the show and I make it a point to read every single one of the reviews we get. Please leave a review right now. Thanks for listening!  

Jim, tell us a little bit about yourself and your work at ACRP.I started my career at Eli Lilly for 24 years before moving to Quintiles, now known as IQVIA, for 5 years. After spending the following five years consulting, I became the executive director for ACRP.ACRP recently released some data on the state of the clinical trial workforce. I want to dive into what that data revealed. What trends are you seeing in clinical research career opportunities right now?Recent trends in clinical research career opportunities include a disproportionate growth rate of clinical studies compared to the size of the workforce. We believe strongly that we need to close this gap to get therapies to market as quickly as possible.What might a typical career path look like for someone entering the clinical research industry? Do you need to have a scientific background to be successful in clinical research?Right now, I'm not sure there is a typical career path. Most people who end up in clinical research typically come into their positions by chance. That lack of clarity in career entrance and development is a huge problem.In previous episodes, we’ve heard about the importance of recruiting diverse patients for clinical research. Can you speak on the importance of having a diverse workforce in clinical research as well?We feel like we can kill two birds with one stone so to speak. Growing the diversity of the workforce can in turn grow the diversity of those enrolled in clinical trials.What are the potential consequences of clinical trial growth outpacing clinical trial employment?A potential consequence of the outpace in growth between clinical studies and the workforce in clinical studies is that we won’t have enough people to conduct studies to the extent that we need them to. This will be a bottleneck in the development pipeline.What can sites, sponsors or CROs do to encourage interest in joining the clinical research industry?The more variance you have, the more likely you are to have poor quality, and unfortunately that’s the case in clinical research now. It’s critical that we begin defining competencies for positions in our industry. When we gain industry alignment around these competencies, we can begin to train individuals on them, and then validate that people actually have them. This is the only area in healthcare where there are no real standardized requirements or competencies. We need to change that.

  Deepa Dahal and Karen Dindial are established biopharmaceutical industry consultants and the co-founders of DKI Health. DKI Health is a healthcare consultancy that offers a range of services, specializing in commercial strategy, policy, healthcare advocacy, and market access. In addition to founding DKI Health, Deepa’s fifteen-year career has included working at Quintiles, IMS Health (IQVIA), and Campbell Alliance (Inventiv). Karen’s work in the healthcare space spans two decades, and also includes time serving at Quintiles, along with Medidata and the Centers for Disease Control and Prevention at the National Institute for Occupational Safety and Health.   Today, Deepa and Karen join me to discuss DKI Health and their shared vision and passion for their consulting work. They share their co-founder relationship and how they use their complementary skill sets to work together effectively and deliver on their brand’s core competencies. Deepa and Karen also highlight the value of relationship building, the importance of patient voices, and their experience as minority women in their industry.       “They don’t hire a company. They hire the people that come with it.” - Deepa Dahal       Today on When She Founded: How Deepa and Karen met and what led them to launch DKI Health The market needs DKI Health addresses and some therapeutic areas the consultancy focuses on The gap that Deepa and Karen saw in terms of women’s leadership in the industry The value that Deepa and Karen have found in having a co-founder The power of relationships and reputation in building a successful brand in a crowded market How DKI Health differentiates itself through patient-centricity and why this matters The different types of stakeholders that DKI Health works with and the types of projects Deepa and Karen enjoy working on The importance of being transparent and honest about what you can and cannot offer as a brand Their early advocates as they launched their consultancy DKI Health’s plans for scaling and expanding the business and insights into DKI Health’s hiring strategy     Connect with Deepa Dahal and Karen Dindial: DKI Health Deepa Dahal on LinkedIn Karen Dindial on LinkedIn DKI Health on LinkedIn DKI Health on Twitter White Paper: Serving Patients, Improving Healthcare: The Growing Role of Patient Advocates         Subscribe, Rate & Share Your Favorite Episodes!   Thanks for tuning into today’s episode of When She Founded with your host, Somer Hamrick. If you enjoyed this episode, please head over to Apple Podcasts to subscribe and leave a rating and review.   Don’t forget to visit our website, connect with Somer on LinkedIn, and share your favorite episodes across social media.                        

Knowing your purpose is one thing, being able to share it powerfully is something else all together. Susan Heaton-Wright shares her insights on finding your voice and sharing it with power and authenticity. The part that I love is when she talks about making things as easy possible for people to understand you. Bio: Susan Heaton-Wright is an impact, communications and speaking expert for emerging leaders and the creator of the Superstar Communicator™ methodology. She is an international speaker; the MD of award winning music company, Viva Live Music, podcaster and a former prize winning international opera singer. She delivers seminars, workshops and individual training for many companies including Astra Zeneca, Shell, Microsoft, AXA, the NHS and Quintiles. As a CPD accredited speaker, she regularly delivers speeches and seminars to lawyers, accountants and finance professionals, as well as leaders and emerging leaders in organisations. Many of her clients go on to be interviewed on Sky News and BBC as well as speaking at industry conferences. She is regularly interviewed on BBC Radio Five Live; BBC2, local radios and international podcasts. Susan has contributed to articles in Forbes, The Guardian, Huffington Post, Thrive Global, The Scotsman and trade publications. In 2020, she was named as an #ialso 100 top inspirational female entrepreneurs in UK. Susan is a Fellow of the Royal Geographical Society, The Royal Society of Arts and the Incorporated Society of Musicians. She leads a project of musicians in Greece annually, to deliver music workshops to refugees in Athens as part of the ‘Love without Borders' charity.

Susan Heaton-Wright is a Virtual impact, communications and speaking coach for emerging leaders and creator of the Superstar Communicator™ programme. She is an international speaker; virtual speaker; panellist; podcast host, the MD of award winning music company, Viva Live Music and a former prize winning international opera singer. She delivers seminars, webinars, virtual coaching, workshops and individual coaching for many companies including Astra Zeneca, Microsoft, Shell, AXA and Quintiles. She is regularly interviewed on BBC Radio Five Live; BBC2, local radios and international podcasts. In 2020 she was named in the #ialso 100 top inspirational female entrepreneurs with f:entrepreneur. Susan has studied Neuroscience on the Neuroscience Professional Development Programme, accredited with the British Psychological Society. Susan has contributed to articles in Forbes, The Guardian, Huffington Post, Thrive Global, The Scotsman and trade publications. Susan is a fully qualified teacher ; a Fellow of the Royal Geographical Society, The Royal Society of Arts and the Incorporated Society of Musicians. She leads a project of musicians in Greece annually, to deliver music workshops to refugees in Athens as part of the ‘Love without Borders' charity. I am a Public Speaker Virtual Speaker and panellist: speaking at conferences, Professional organisations, online summits, virtual conferences and trade shows. and am interviewed on BBC Radio, TV and on international podcasts, as well as contributing to business articles. Superstar Communicator: using the Superstar Communicator™ programme I created, I coach emerging leaders, executives, entrepreneurs and graduates to make an impact when they speak through developing a series of skills virtually and face to face. I focus on emerging leaders and a number of my clients have appeared on the media and in prestigious conferences. Many of my training courses are CPD accredited. As the CEO and Creative Director of Viva Live music, I have founded and led an award winning live music company. My background was initially in opera and music theatre as a performer and I've had over 25 years experience of performing, arranging and leading a wide variety of entertainment options for corporate and private events including Gala Dinners, Drinks Receptions, Award Ceremonies, Festivals, Weddings and Celebrations. Learn more about your ad choices. Visit megaphone.fm/adchoices

Guest: James Oldroyd- Professor James Oldroyd is an associate professor of Strategy at the Marriott School of Management, Brigham Young University and the Ford Motor/Richard Cook Research Fellow. He received his Ph.D. from the Kellogg School of Management at Northwestern University in 2007. He was an associate professor of management at SKK-GSB in Seoul, South Korea for five years and an assistant professor of international business at The Ohio State University for three years. His research explores the intersection of networks and knowledge flows. This work has been published in outlets such as the Academy of Management Review, Organization Science and Harvard Business Review. He teaches courses on strategy, strategy implementation, international business, and negotiations to undergraduates, MBAs, and executives. In addition, to teaching at SKK, OSU and BYU, he has taught at the Indian School of Business and the University of North Carolina. He is actively involved in delivering custom leadership training courses for numerous companies including Samsung, Doosan, SK, Quintiles, and insidesales.Connect with James on LinkedIn and check out the BYU Marriot website.3 Key Findings from Bot research:Rapid Response Look at the whole funnelFirst figure out how to get your customer to engage.  Connect with Billy and Chatfunnels!Billy on LinkedIn and Twitter.Chatfunnels on LinkedIn, Facebook, Twitter, and Instagram.Check out our blog and get a free bot & live chat analysis!Take a screenshot of the podcast and post using the #digitalconversations!

Richard Selfridge and James Pembroke’s monthly look at Education Data. Ian Stokes (https://twitter.com/ianstokesed) - New EIF inspections - are Ofsted still 'judging by numbers'? https://ianstokes.org/investigations Mary Bousted - Ofsted's Framework asks way too much of Primary Staff https://www.tes.com/news/ofsteds-framework-asks-way-too-much-primary-staff Don't panic about quintiles - https://www.sigplus.co.uk/2019/10/dont-panic-about-quintiles/ Quntiles part 2 - How to be above and below average at the same time https://www.sigplus.co.uk/2019/10/quintiles-part-2-how-to-be-above-and-below-average-at-the-same-time/ Databusting for Schools on tour! https://www.databustingforschools.co.uk/supporting-schools.html Get in touch via https://twitter.com/Jack_Marwood or https://twitter.com/Jpembroke Leave us a voice message here: https://anchor.fm/databusters/message --- Send in a voice message: https://anchor.fm/databusters/message

Fishermen Labs, Common Foods, and Sonar TeamsIn 2014, Eden Chen launched Fishermen Labs, a company specializing in app and website development, and virtual reality and augmented reality for brands and startups. His clients include Sony, United Nations, HTC, Qualcomm, Quintiles, NFL and NBC. He also founded Knife and Fox, a design studio for brands and startups. Chen was recently in Forbes 30 Under 30.https://www.linkedin.com/in/edechen/

Susan Heaton Wright- Susan Heaton-Wright is an impact, communications and speaking trainer for emerging leaders and the creator of the Superstar Communicator™ philosophy. She is an international speaker; the MD of award winning music company, Viva Live Music, podcaster and a former prize winning international opera singer.  She delivers seminars, workshops and individual training for many companies including Astra Zeneca, Shell, AXA and Quintiles. She is regularly interviewed on BBC Radio Five Live; BBC2, local radios and international podcasts. Susan has contributed to articles in Forbes, The Guardian, Huffington Post, Thrive Global, The Scotsman and trade publications.  Susan is a Fellow of the Royal Geographical Society, The Royal Society of Arts and the Incorporated Society of Musicians. She leads a project of musicians in Greece annually, to deliver music workshops to refugees in Athens as part of the ‘Love without Borders’ charity. Listen to another #12minconvo

Susan Heaton-Wright is an impact, communications and speaking trainer for emerging leaders and the creator of the Superstar Communicator™ philosophy. She is an international speaker; the MD of award winning music company, Viva Live Music, podcaster and a former prize winning international opera singer. She delivers seminars, workshops and individual training for many companies including Astra Zeneca, Shell, AXA and Quintiles. She is regularly interviewed on BBC Radio Five Live; BBC2, local radios and international podcasts. Susan has contributed to articles in Forbes, The Guardian, Huffington Post, Thrive Global, The Scotsman and trade publications. Susan is a Fellow of the Royal Geographical Society, The Royal Society of Arts and the Incorporated Society of Musicians. She leads a project of musicians in Greece annually, to deliver music workshops to refugees in Athens as part of the ‘Love without Borders’ charity. If you missed earlier episodes, you can find them on our Grow through International Expansion platform, https://growinternational.org . Our platform is independent, carries no advertising and is not for profit – we seek to deliver useful, valuable content, essential for all those who have interest in international business and global trade.

John Doyle leads the Patient Health & Impact Global Healthcare Innovation Center at Pfizer. His team designs new models for value-based contracting and innovative financing and forges new partnerships across the healthcare sector to facilitate value-based healthcare. Prior to joining Pfizer, John led the Global Enterprise Solutions team at IQVIA, providing technology-enabled real world evidence platforms and research networks to healthcare systems worldwide. John also led the Global Value & Outcomes Center of Excellence at Quintiles, overseeing pricing and market access, policy analysis, and health economics and outcomes research. Recorded live at the 2019 BIO international conference in Philadelphia, this podcast includes in-depth discussions on what value-based pricing is and the challenges to its implementation. John also discusses the Administration’s International Reference Pricing Initiative and offers alternatives that focus on bringing better value to US patients without limiting access.

Welcome to Finance and fury, the Furious Friday edition. Today’s episode is Stages to Socialism Part 2, so if you haven’t listened to last Friday’s episode it might be worthwhile doing so. To start I want to talk about oranges. They’re a delicious fruit, they grow on trees, and then mature. Then you can eat them. They have nutrients, that helps you survive. Have you ever left an orange on the bench too long? It starts getting a small soft soggy area, that slowly expands Then that mould starts to grow, this starts eating the orange and eventually consumes the whole thing I always thought of the Government as mould and the orange as the economy/free market/individuals The free market matures and Individuals get wealthy. Then government starts growing, we ignore the orange, and it rots Can’t blame them, just like companies, or bacteria, every organism has one purpose to multiply and survive. This is the best tactic to last. Unfortunately, it is an organism which doesn’t create, it only redistributes. Spending has to come from somewhere, like the population and companies and paying tax Don’t get me wrong, governments are needed. But the question people disagree on is needed for what? Political Spectrum, it isn’t just left/right, there isn’t a simple way to look at this Think of this political spectrum as an X shaped chart. There are two axis Authoritarian to Libertarian – How much freedom do you have as an individual Government intervention levels/the size of government Rules and regulations that you must follow. On one end you have dictatorships, and the other is anarchy Economic Left (Communism/Socialism) and Economic Right (Capitalism) Control of markets and owning the means of production Property rights for individuals and are there many regulations to follow. Communism is on one end and the free market is on the other Government interventions – Authoritarian to Libertarian Power corrupts and absolute power corrupts absolutely Once a government gets 100% control, the system of government doesn’t reverse that quickly Roll the dice every few years/decades, get a new leader. They may be worse and more corruptible than the last guy Leads to a slow decline in civilisations, for example, Rome with emperors, Medieval Kingdoms with monarchies Chop the head off the snake and the thing crumbles Inefficient – Become so heavy that it crushes itself, and doesn’t operate efficiently. Barriers to entry (Regulations) and How much tax you have to pay (Redistribution) Economic Control and private property Creates four broad spectrums Economic Freedom to legislated equality Personal Freedom to legislate morality Examples NAZIs were authoritarian, with traces of economic left but more socialist Fascists like Mussolini who was very authoritarian. Decent amount of capitalism (But corruption and often nepotism that fails it) Stalin and Lenin were communist, with authoritarian regimes. On the economic left with no private property ownership   Our system Does Democracy Work? A government of the masses. Authority derived through mass expression, What most people want Attitude toward law is that the will of the majority shall regulate Based on deliberation by passion, prejudice, and impulse, without restraint to consequences. We are a free market, democratic country, with socialist policies Military, Police, Health, Public Education, Roads. These are all publicly funded. Doesn’t make us a socialist country, we are a free market This is good – Government is essential in many basic needs. It provides a platform for society to exist How well they do those things is a core component for the success of each country Protection of population Enforcing laws with the judicial system Infrastructure through Planning and contracting How much involvement is where people start disagreeing. Either more or less Government? How much time does anyone have to know what politicians are doing, let alone understanding each individual issue? George Washington once said "It is one of the evils of democratic governments, that the people, not always seeing and frequently misled, must often feel before they can act right; but then evil of this nature seldom fail to work their own cure." It isn’t feasible to expect every citizen to be sufficiently informed and to vote on every law Problems they are trying to solve are complicated and takes time to fully comprehend People are busy with their own lives Democracy can go to Monarchy/Dictator quickly The people tire of their involvement in the mundane processes of legislation and legal administration. Over time they fail to remain properly educated as issues mount and become more complex. The people neglect governmental affairs when times are comfortable and erupt in a firestorm of uncontrolled emotions when times are uncomfortable If you rely on the government and that starts failing you, what do you do? This creates unrest In one of any significant size, dissatisfaction and disorder erupt and the people demand leadership. When this becomes exhausting or dangerous, the people look for a popular, charismatic leader who can bring order and direction to the failing government. As populations and leaders change, the direction the Government sits can start to change   How does a state start moving along these axes? How we go from here to Economic Left/Authoritarianism? Preamble: There are stages to socialism. The first is capitalism and the last is communism. Stages: Stage One — Capitalism: Before any economic or political transformation to socialism there must be capitalism Capitalism is necessary for the transformation into socialism, as only capitalism can produce the necessary vast amounts of wealth as a promise of redistribution Quote from Manifesto of the Communist Party - The bourgeoisie, during its rule of scarce 100 years, has created more massive and more colossal productive forces than have all preceding generations together. Capitalism comes with Freedom and only freedom can create the ‘classes’ of wealth. The proletariat and bourgeoisie Due to freedom of choice, capitalism creates income and economic disparity (inequality) This is the tool that the Fabians use, class warfare and misinformation. The only reason a person is poor is from someone stealing it from them. Giving people no education on how to succeed is the problem. A necessary relationship for the emergence of support for socialism. Marx and Lenin all knew this. Without capitalism, there is insufficient wealth for redistribution = Economies will stagnate and socialism will become unaffordable. Just like in Venezuela. Four Laws of Economic Freedom Prosperity - the climate of wholesome stimulation protected by law. There are four laws of economic freedom which a nation must maintain if its people are to prosper at the maximum level, there are: The Freedom to try. – Equal opportunity The Freedom to buy. The Freedom to sell. The Freedom to fail – Incentive reduction This creates large inequalities, however, there are higher standards of living for everyone People who are considered ‘poor’ would be well off in most of the rest of the world James Madison - "Where a majority are united by a common sentiment and have an opportunity, the rights of the minor party become insecure."   Stage Two — Transition to Socialism: Getting the power to change the rules “dictatorship of the proletariat” – This is Mob Rule or a government where decisions are made by democratically elected representatives of the working class. However, once elected, the population has little say in policies made Side with the most votes wins. How do you win votes? Carrot, no carrot or Stick approach Once a Government is elected (or form majority) They can put a few policies in place, through the normal channels Stage Three — Primary & Secondary Socialism: What to do with legislative ability? Increase control and power of government. This includes educational, medical, or similar services. Until controlling every area of life Completed through legislative powers: The government will have powers to give it a necessary control over the populace through judicial processes Private ownership of property still exists only as long as unjust and excessive ownership is abolished. Progressive taxation policy: Taxation of 47% of income, total taxes of 60% (GST, FBT, rates, land taxes) Disincentivise those who work “discrimination is employed against the bourgeoisie” – Create the vanishing of upper and middle classes “important element of a democratic precedent” – Create policies to reduce the ability of prosperity Need to create more people in poverty (or disenfranchised) to increase voting base Done by reduction of employment conditions, taxing companies (payroll tax), make it hard to operate While operating as a competitor for employment Establish security, Through redistribution via force (law and penalty) The goal is to centralise the means of production under the state Slowly reduce the productivity of the private sector, making the government and private sector competitors The quality of citizen’s life should have been improved, through redistribution to the majority, so the public opinion remains warm towards socialism and supports its continued development Done through welfare and free handouts. A short-term improvement for long-term consequences Play this out – Top 10% pay 52% of the tax (working age), how easy for the bottom 90% to get them to pay double? 80% of people to get 20% to pay double – Top 20% pay 71% of income tax collected 5 Quintiles or 5 Groups: The bottom 20% to 20%: Bottom 2, 40% = 0%, 3rd = 7%, 4th  = 21%, 5th  = 71% Bottom quintile benefits worth more than 320 times what they paid in tax and the second-lowest quintile achieves 10 times what they paid in tax Summary: Freedom is better: Paying attention to the mold growing, the social spending, government regulations, and areas of service Smaller increases in spending over time aren’t noticeable. All this spending has to come from somewhere. This will be taxes or borrowing What works is trying to increase people’s freedom Freedom to try and freedom to fail, A merit-based system In ancient times survival was hard and those more capable tended to survive slightly better When we lose challenge we start to devolve and have atrophy of the skills to survive. The bar of merit to survive drops significantly Where does it cross the line for you? Having 1/3rd of your money taken away from you? Who you can marry? – Big thing recently - but why does the government need to be involved? What you can say? – Increasing regulation on speech Where your money is spent? What changes do you want to be made? Thanks for listening today, and let me know what you think over at the Finance and Fury website here.  

Enjoy this BONUS Episode - Q & A with Mike Schultz, President of RAIN Group A few highlights... we talk about:  New research proving that cold calls and outbound still works to generate sales Insights into what buyers wants from sellers Which channels work, in what context and sequence, to create sales pipeline You also like: Top Performing Sales Propsecting More about our guest: President of RAIN Group, Mike Schultz is world-renowned as a consultant and sales expert. He is co-author of several books including the Wall Street Journal bestseller Rainmaking Conversations: How to Influence, Persuade, and Sell in Any Situation (Wiley, 2011) and Insight Selling: Surprising Research on What Sales Winners Do Differently (Wiley, 2014). He was named the Top Sales Thought Leader globally in 2011 by Top Sales Awards. Mike and the team at RAIN Group have worked with organizations such as Toyota, Monitor-Deloitte, Harvard Business School, Oracle, Fidelity Investments, Ryder, Quintiles, UL, Navigant Consulting, Hitachi, Lee Hecht Harrison, Lowe's, and hundreds of others to unleash sales performance. News outlets such as Business Week, The Globe and Mail, Inc. Magazine, MSNBC, and hundreds of others have featured Mike's original articles and white papers, and frequently quote him as an expert. Mike's most recent research includes What Sales Winners Do Differently,Top Performance in Strategic Account Management, and theTop-Performing Sales Organization. Along with his books, Mike has written hundreds of articles, case studies, research reports, white papers, and other publications in the areas of selling and marketing. He also writes for the RAIN Group Sales Blog. Mike is also the director of the RAIN Group Center for Sales Research. Mike is a graduate of Brandeis University in Waltham, MA with a B.A. in American Studies, and holds an MBA from the F.W. Olin Graduate School of Business at Babson College. Mike is currently on the faculty teaching sales at the Brandeis International Business School. Mike also enjoys fly fishing and golf, and actively studies and teaches the traditional martial arts of Seirenkai Karate and Jujitsu, holding the ranks of third degree black belt and Sensei. He lives on a lake west of Boston.

Special Guest: Debra Corey, Two-Time Author, Speaker and HR Leader, Global Head of Reward at Reward Gateway. Debra shares information from her newly published best-selling book, 'Build it: The rebel playbook for employee engagement' including the need for organisations to challenge the status quo in how they treat their employees and how they engage with their workforce. Join us as Debra shares tips, tools and real-life stories taken from her book to help you learn how to be an engagement 'rebel', and stand out as a great place to work. Debra Corey is a two-time author, speaker and HR leader with over 20 years experience. She is currently the global head of reward at Reward Gateway, previously holding roles at global organisations such as Gap Inc., Honeywell, Quintiles and Merlin Entertainment. Her recent book which she co-authored with Glenn Elliott is titled 'Build it: The rebel playbook for Employee Engagement, and has been called “Your all-things-necessary guide to employee engagement” by Daniel Pink, author of When, and said to “Give you ideas, debates, great arguments and, most of all, hope” by Margaret Heffernan, author of Willful Blindness. Host: Jo Dodds

In This episode we interviewed a CRA who has worked her way up in clinical research from an IQVIA Intern to a Clinical Research Associate. Many people are constantly asking about how they can get there start in clinical research and the best way to get their foot in the door to become a clinical research associate. In this episode, we discuss ways and the best positions for people to get their start in the clinical research field. Whether it is to start as an intern at a company like Syneos health, IQVIA formerly Quintiles, PPD or Parexels, or some other way to get in the industry. This interview is jam packed with tips to get your foot in the door to clinical research and reach the dream job of being a Clinical Research Associate. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/clinical-research-podcast/message Support this podcast: https://anchor.fm/clinical-research-podcast/support

Enjoy this BONUS Episode - Q & A with Mike Schultz, President of RAIN Group A few highlights... we talk about:  New research proving that cold calls and outbound still works to generate sales Insights into what buyers wants from sellers Which channels work, in what context and sequence, to create sales pipeline More about our guest:   President of RAIN Group, Mike Schultz is world-renowned as a consultant and sales expert. He is co-author of several books including the Wall Street Journal bestseller Rainmaking Conversations: How to Influence, Persuade, and Sell in Any Situation (Wiley, 2011) and Insight Selling: Surprising Research on What Sales Winners Do Differently (Wiley, 2014). He was named the Top Sales Thought Leader globally in 2011 by Top Sales Awards. Mike and the team at RAIN Group have worked with organizations such as Toyota, Monitor-Deloitte, Harvard Business School, Oracle, Fidelity Investments, Ryder, Quintiles, UL, Navigant Consulting, Hitachi, Lee Hecht Harrison, Lowe's, and hundreds of others to unleash sales performance. News outlets such as Business Week, The Globe and Mail, Inc. Magazine, MSNBC, and hundreds of others have featured Mike's original articles and white papers, and frequently quote him as an expert. Mike's most recent research includes What Sales Winners Do Differently, Top Performance in Strategic Account Management, and the Top-Performing Sales Organization. Along with his books, Mike has written hundreds of articles, case studies, research reports, white papers, and other publications in the areas of selling and marketing. He also writes for the RAIN Group Sales Blog. Mike is also the director of the RAIN Group Center for Sales Research. Mike is a graduate of Brandeis University in Waltham, MA with a B.A. in American Studies, and holds an MBA from the F.W. Olin Graduate School of Business at Babson College. Mike is currently on the faculty teaching sales at the Brandeis International Business School. Mike also enjoys fly fishing and golf, and actively studies and teaches the traditional martial arts of Seirenkai Karate and Jujitsu, holding the ranks of third degree black belt and Sensei. He lives on a lake west of Boston.

Show description/summary:1) Serum neurofilament light chain as a biomarker for mild traumatic brain injury in contact sports2) What's Trending: Biomarker validation and precision medicine in Parkinson disease.This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 9, 2017 issue of Neurology. In the first segment, Dr. Kristen Heinan talks with Dr. Pashtun Shahim about his paper on serum neurofilament light chain as a biomarker for mild traumatic brain injury in contact sports. In the next part of the podcast Dr. Alberto Espay focuses his discussion with Dr. David Standaert on biomarker validation and precision medicine in Parkinson disease. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Standaert serves on scientific advisory boards for the American Parkinson Disease Association; serves on the DSMB for Shire/Biropharma; received honoraria from the Movement Disorder Society and Georgia Regents University; is Associate Editor for Movement Disorders; receives publishing royalties for Movement Disorders (McGraw-Hill Publishers, 3rd ed.); consulted for Serina Therapeutics, Kirchner Group, Teva Neuroscience, Abbvie, and the U.S. Attorney's Office; receives research support from Abbvie, Acerta Pharmaceuticals, Ceregene, Quintiles, NIH, Alabama Department of Commerce, American Parkinson Disease Association, Michael J. Fox Foundation for Parkinson Research, Bachmann-Strauss Dystonia & Parkinson Foundation, and the Dystonia Medical Research Foundation.All other participants report no disclosures.

Adam Tanner is the author of "Our Bodies, Our Data", which tells the story of a hidden dark market in drug prescription and other medical data. In recent years hackers have been able to steal health data on a massive scale -- remember Anthem? In this second part of our interview, we explore the implications of hacked medical data. If hackers get into a data brokers' drug databases and combine with previously stolen medical insurance records, will they rule the world? Transcript Inside Out Security: Today, I'd like to welcome Adam Tanner. Adam is a writer-in-residence at Harvard University's Institute for Quantitative Social Science. He's written extensively on data privacy. He's the author of What Stays In Vegas: The World of Personal Data and the End of Privacy As We Know It. His articles on data privacy have appeared in Scientific American, Forbes, Fortune, and Slate. And he has a new book out, titled "Our Bodies, Our Data," which focuses on the hidden market in medical data. Welcome, Adam. Adam Tanner: Well, I'm glad to be with you. IOS: We've also been writing about medical data privacy for our Inside Out Security blog. And we're familiar with how, for example, hospital discharge records can be legally sold to the private sector. But in your new book, and this is a bit of a shock to me, you describe how pharmacies and others sell prescription drug records to data brokers. Can you tell us more about the story you've uncovered? AT: Basically, throughout your journey as a patient into the healthcare system, information about you is sold. It has nothing to do with your direct treatment. It has to do with commercial businesses wanting to gain insight about you and your doctor, largely, for sales and marketing. So, take the first step. You go to your doctor's office. The door is shut. You tell your doctor your intimate medical problems. The information that is entered into the doctor's electronic health system may be sold, commercially, as may the prescription that you pick up at the pharmacy or the blood tests that you take or the urine tests at the testing lab. The insurance company that pays for all of this or subsidizes part of this, may also sell the information. That information about you is anonymized.  That means that your information contains your medical condition, your date of birth, your doctor's name, your gender, all or part of your postal zip code, but it doesn't have your name on it. All of that trade is allowed, under U.S. rules. IOS: You mean under HIPAA? AT: That's right. Now this may be surprising to many people who would ask this question, "How can this be legal under current rules?" Well, HIPAA says that if you take out the name and anonymize according to certain standards, it's no longer your data. You will no longer have any say over what happens to it. You don't have to consent to the trade of it. Outsiders can do whatever they want with that. I think a lot of people would be surprised to learn that. Very few patients know about it. Even doctors and pharmacists and others who are in the system don't know that there's this multi-billion-dollar trade. IOS:Right … we've written about the de-identification process, which it seems like it's the right thing to do, in a way, because you're removing all the identifiers, and that includes zip code information, other geo information. It seems that for research purposes that would be okay. Do you agree with that, or not? AT: So, these commercial companies, and some of the names may be well-known to us, companies such as IBM Watson Health, GE, LexisNexis, and the largest of them all may not be well-known to the general public, which is Quintiles and IMS. These companies have dossiers on hundreds of millions of patients worldwide. That means that they have medical information about you that extends over time, different procedures you've had done, different visits, different tests and so on, put together in a file that goes back for years. Now, when you have that much information, even if it only has your date of birth, your doctor's name, your zip code, but not your name, not your Social Security number, not things like that, it's increasingly possible to identify people from that. Let me give you an example. I'm talking to you now from Fairbanks, Alaska, where I'm teaching for a year at the university here. I lived, before that, in Boston, Massachusetts, and before that, in Belgrade, Serbia. I may be the only man of my age who meets that specific profile! So, if you knew those three pieces of information about me and had medical information from those years, I might be identifiable, even in a haystack of millions of different other people. IOS: Yeah …We have written about that as well in the blog. We call these quasi-identifiers. They're not the traditional kind of identifiers, but they're other bits of information, as you pointed out, that can be used to sort of re-identify. Usually it's a small subset, but not always. And that this information would seem also should be protected as well in some way. So, do you think that the laws are keeping up with this? AT: HIPAA was written 20 years ago, and the HIPAA rules say that you can freely trade our patient information if it is anonymized to a certain standard. Now, the technology has gone forward, dramatically, since then. So, the ability to store things very cheaply and the ability to scroll through them is much more sophisticated today than it was when those rules came into effect. For that reason, I think it's a worthwhile time to have a discussion now. Is this the best system? Is this what we want to do? Interestingly, the system of the free trade in our patient information has evolved because commercial companies have decided this is what they'd want to do. There has not been an open public discussion of what is best for society, what is best for patients, what is best for science, and so on. This is just a system that evolved. I'm saying, in writing this book, "Our Bodies, Our Data," that it is maybe worthwhile that we re-examine where we're at right now and say, "Do we want to have better privacy protection? Do we want to have a different system of contributing to science than we do now?" IOS: I guess what also surprised me was that you say that pharmacies, for example, can sell the drug records, as long as it's anonymized. You would think that the drug companies would be against that. It's sort of leaking out their information to their competitors, in some way. In other words, information goes to the data brokers and then gets resold to the drug companies. AT: Well, but you have to understand that everybody in what I call this big-data health bazaar is making money off of it. So, a large pharmacy chain, such as CVS or Walgreen's, they may make tens of millions of dollars in selling copies of these prescriptions to data miners. Drug companies are particularly interested in buying this information because this information is doctor-identified. It says that Dr. Jones in Pittsburgh prescribes drug A almost all the time, rather than drug B. So, the company that makes drug B may send a sales rep to the doctor and say, "Doctor, here's some free samples. Let's go out to lunch. Let me tell you about how great drug B is." So, this is because there exists these doctor profiles on individual doctors across the country, that are used for sales and marketing, for very sophisticated kind of targeting. IOS: So, in an indirect way, the drug companies can learn about the other drug companies' sales patterns, and then say, "Oh, let me go in there and see if I can take that business away." Is that sort of the way it's working? AT: In essence, yes. The origins of this trade date back to the 1950s. In its first form, these data companies, such as IMS Health, what they did was just telling companies what drugs sold in what market. Company A has 87% of the market. Their rival has 13% of the market. When medical information began to become digitized in the 1960s and '70s and evermore since then, there was a new opportunity to trade this data. So, all of a sudden, insurance companies and middle-men connecting up these companies, and electronic health records providers and others, had a product that they could sell easily, without a lot of work, and data miners were eager to buy this and produce new products for mostly the pharmaceutical companies, but there are other buyers as well. IOS:  I wanted to get back to another point you mentioned, in that even with anonymized data records of medical records, with all the other information that's out there, you can re-identify or at least limit, perhaps, the pool of people who that data would apply to. What's even more frightening now is that hackers have been stealing health records like crazy over the last couple of years. So, there's a whole dark market of hacked medical data that, I guess, if they got into this IMS database, they would have the keys to the kingdom, in a way. Am I being too paranoid here? AT: Well, no, you correctly point out that there has been a sharp upswing in hacking into medical records. That can happen into a small, individual practice, or it could happen into a large insurance company. And in fact, the largest hacking attack of medical records in the last couple of years has been into Anthem Health, which is the Blue Cross Blue Shield company. Almost 80 million records were hacked in that. So even people that did... I was hacked in that, even though I was not, at the time, a customer of them or had never been a customer of them, but they... One company that I dealt with outsourced to someone else, who outsourced to them. So, all of a sudden, this information can be in circulation. There’s a government website people can look at, and you'll see, every day or two, there are new hackings. Sometimes it involves a few thousand names and an obscure local clinic. Sometimes it'll be a major company, such as a lab test company, and millions of names could be impacted. So, this is something definitely to be concerned about. Yes, you could take these hacked records and match them with anonymized records to try to figure out who people are, but I should point out that there is no recorded instance of hackers getting into these anonymized dossiers by the big data miners. IOS: Right. We hope so! AT: I say recorded or acknowledged instance. IOS: Right. Right. But there's now been sort of an awareness of cyber gangs and cyber terrorism and then the use of, let's say, records for blackmail purposes. I don't want to get too paranoid here, but it seems like there's just a potential for just a lot of bad possibilities. Almost frightening possibilities with all this potential data out there. AT: Well, we have heard recently about rumors of an alleged dossier involving Donald Trump and Russia. IOS: Exactly. AT: And information that... If you think about what kind of information could be most damaging or harmful to someone, it could be financial information. It could be sexual information, or it could be health information. IOS: Yeah, or someone using... or has a prescription to a certain drug of some sort. I'm not suggesting anything, but that... All that information together could have sort of lots of implications, just, you know, political implications, let's say. AT: I mean if you know that someone takes a drug that's commonly used for a mental health problem, that could be information used against someone. It could be used to deny them life insurance. It could be used to deny them a promotion or a job offer. It could be used by rivals in different ways to humiliate people. So, this medical information is quite powerful. One person who has experienced this and spoken publicly about it is the actor, Charlie Sheen. He tested positive for HIV. Others somehow learned of it and blackmailed him. He said he paid millions of dollars to keep that information from going public, before he decided finally that he would stop paying it, and he'd have to tell the world about his medical condition. IOS: Actually I was not aware of the payments he was making. That's just astonishing. So, is there any hope here? Do you see some remedies, through maybe regulations or enforcement of existing laws? Or perhaps we need new laws? AT: As I mentioned, the current rules, HIPAA, allows for the free trade of your data if it's anonymized. Now, I think, given the growth of sophistication in computing, that we should change what the rule is and to define our medical data as any medical information about us, whether or not it's anonymized. So, if a doctor is writing in the electronic health record, you should have a say as to whether or not that information is going to be used elsewhere. A little side point I should mention. There are a lot of good scientists and researchers who want data to see if they can gain insights into disease and new medications. I think people should have the choice whether or not they want to contribute to those efforts. So, you know, there's a lot of good efforts. There's a government effort under way now to gather a million DNA samples from people to make available to science. So, if people want to participate in that, and they think that's good work, they should definitely be encouraged to do so, but I think they should have the say and decide for themselves. And so far, we don't really have that system. So, by redefining what patient data is, to say, "Medical information about a patient, whether or not it's anonymized," I think that would give us the power to do that. IOS: So effectively, you're saying the patient owns the data, is the owner, and then would have to give consent for the data to be used. Is that, about right? AT: I think so. But on the other hand, as I mentioned, I've written this book to encourage this discussion. The problem we have right now is that the trade is so opaque. Companies are extremely reluctant to talk about this commercial trade. So, they do occasionally say that, "Oh, this is great for science and for medicine, and all of these great things will happen." Well, if that is so fantastic, let's have this discussion where everyone will say, "All right. Here's how we use the data. Here's how we share it. Here's how we sell it." Then let people in on it and decide whether they really want that system or not. But it's hard to have that intelligent policy discussion, what's best for the whole country, if industry has decided for itself how to proceed without involving others. IOS: Well, I'm so glad you've written this book. This will, I'm hoping, will promote the discussion that you're talking about. Well, this has been great. I want to thank you for the interview. So, by the way, where can our listeners reach out to you on social media? Do you have a handle on Twitter? Or Facebook? AT: Well, I'm @datacurtain  and I have a webpage, which is http://adamtanner.news/ IOS: Wonderful. Thank you very much, Adam.

My guest is John Reites, an executive intrapreneur turned digital health entrepreneur. You may have seen him on stage talking about innovation as a digital health evangelist for a contract research organization.   John spent over 14 years leading global drug development and healthcare innovation at Quintiles where he also led internal startups as the head of digital health acceleration.  Late last year he decided to make the jump from global giant and is now the Chief Product Officer and Partner at THREAD Research based in North Carolina. THREAD contributed to 4 of the first 8 studies that were done with Apple’s ResearchKit and they work with Biopharmaceutical companies, CROs and healthcare providers to provide a platform to transform remote patient research and care.  On this episode we talk about the use of tools like Apple’s Health Kit, Research Kit and Care Kit as well as another platform that works for Android. We cover a lot of ground so be sure to check out the complete show notes by visiting our website at DigitalHealthToday.com/17. Learn more about your ad choices. Visit megaphone.fm/adchoices

Adam Tanner is the author of "Our Bodies, Our Data", which tells the story of a hidden dark market in drug prescription and other medical data. Adam explains how the sale of "anonymized" data is a multi-billion dollar business not covered by HIPPA rules. In this first part of our interview, we learn from Adam how the medical data brokers got started and why it's legal. Transcript Inside Out Security: Today, I'd like to welcome Adam Tanner. Adam is a writer-in-residence at Harvard University's Institute for Quantitative Social Science. He's written extensively on data privacy. He's the author of What Stays In Vegas: The World of Personal Data and the End of Privacy As We Know It. His articles on data privacy have appeared in Scientific American, Forbes, Fortune, and Slate. And he has a new book out, titled "Our Bodies, Our Data," which focuses on the hidden market in medical data. Welcome, Adam. Adam Tanner: Well, I'm glad to be with you. IOS: We've also been writing about medical data privacy for our Inside Out Security blog. And we're familiar with how, for example, hospital discharge records can be legally sold to the private sector. But in your new book, and this is a bit of a shock to me, you describe how pharmacies and others sell prescription drug records to data brokers. Can you tell us more about the story you've uncovered? AT: Basically, throughout your journey as a patient into the healthcare system, information about you is sold. It has nothing to do with your direct treatment. It has to do with commercial businesses wanting to gain insight about you and your doctor, largely, for sales and marketing. So, take the first step. You go to your doctor's office. The door is shut. You tell your doctor your intimate medical problems. The information that is entered into the doctor's electronic health system may be sold, commercially, as may the prescription that you pick up at the pharmacy or the blood tests that you take or the urine tests at the testing lab. The insurance company that pays for all of this or subsidizes part of this, may also sell the information. That information about you is anonymized.  That means that your information contains your medical condition, your date of birth, your doctor's name, your gender, all or part of your postal zip code, but it doesn't have your name on it. All of that trade is allowed, under U.S. rules. IOS: You mean under HIPAA? AT: That's right. Now this may be surprising to many people who would ask this question, "How can this be legal under current rules?" Well, HIPAA says that if you take out the name and anonymize according to certain standards, it's no longer your data. You will no longer have any say over what happens to it. You don't have to consent to the trade of it. Outsiders can do whatever they want with that. I think a lot of people would be surprised to learn that. Very few patients know about it. Even doctors and pharmacists and others who are in the system don't know that there's this multi-billion-dollar trade. IOS:Right … we've written about the de-identification process, which it seems like it's the right thing to do, in a way, because you're removing all the identifiers, and that includes zip code information, other geo information. It seems that for research purposes that would be okay. Do you agree with that, or not? AT: So, these commercial companies, and some of the names may be well-known to us, companies such as IBM Watson Health, GE, LexisNexis, and the largest of them all may not be well-known to the general public, which is Quintiles and IMS. These companies have dossiers on hundreds of millions of patients worldwide. That means that they have medical information about you that extends over time, different procedures you've had done, different visits, different tests and so on, put together in a file that goes back for years. Now, when you have that much information, even if it only has your date of birth, your doctor's name, your zip code, but not your name, not your Social Security number, not things like that, it's increasingly possible to identify people from that. Let me give you an example. I'm talking to you now from Fairbanks, Alaska, where I'm teaching for a year at the university here. I lived, before that, in Boston, Massachusetts, and before that, in Belgrade, Serbia. I may be the only man of my age who meets that specific profile! So, if you knew those three pieces of information about me and had medical information from those years, I might be identifiable, even in a haystack of millions of different other people. IOS: Yeah …We have written about that as well in the blog. We call these quasi-identifiers. They're not the traditional kind of identifiers, but they're other bits of information, as you pointed out, that can be used to sort of re-identify. Usually it's a small subset, but not always. And that this information would seem also should be protected as well in some way. So, do you think that the laws are keeping up with this? AT: HIPAA was written 20 years ago, and the HIPAA rules say that you can freely trade our patient information if it is anonymized to a certain standard. Now, the technology has gone forward, dramatically, since then. So, the ability to store things very cheaply and the ability to scroll through them is much more sophisticated today than it was when those rules came into effect. For that reason, I think it's a worthwhile time to have a discussion now. Is this the best system? Is this what we want to do? Interestingly, the system of the free trade in our patient information has evolved because commercial companies have decided this is what they'd want to do. There has not been an open public discussion of what is best for society, what is best for patients, what is best for science, and so on. This is just a system that evolved. I'm saying, in writing this book, "Our Bodies, Our Data," that it is maybe worthwhile that we re-examine where we're at right now and say, "Do we want to have better privacy protection? Do we want to have a different system of contributing to science than we do now?" IOS: I guess what also surprised me was that you say that pharmacies, for example, can sell the drug records, as long as it's anonymized. You would think that the drug companies would be against that. It's sort of leaking out their information to their competitors, in some way. In other words, information goes to the data brokers and then gets resold to the drug companies. AT: Well, but you have to understand that everybody in what I call this big-data health bazaar is making money off of it. So, a large pharmacy chain, such as CVS or Walgreen's, they may make tens of millions of dollars in selling copies of these prescriptions to data miners. Drug companies are particularly interested in buying this information because this information is doctor-identified. It says that Dr. Jones in Pittsburgh prescribes drug A almost all the time, rather than drug B. So, the company that makes drug B may send a sales rep to the doctor and say, "Doctor, here's some free samples. Let's go out to lunch. Let me tell you about how great drug B is." So, this is because there exists these doctor profiles on individual doctors across the country, that are used for sales and marketing, for very sophisticated kind of targeting. IOS: So, in an indirect way, the drug companies can learn about the other drug companies' sales patterns, and then say, "Oh, let me go in there and see if I can take that business away." Is that sort of the way it's working? AT: In essence, yes. The origins of this trade date back to the 1950s. In its first form, these data companies, such as IMS Health, what they did was just telling companies what drugs sold in what market. Company A has 87% of the market. Their rival has 13% of the market. When medical information began to become digitized in the 1960s and '70s and evermore since then, there was a new opportunity to trade this data. So, all of a sudden, insurance companies and middle-men connecting up these companies, and electronic health records providers and others, had a product that they could sell easily, without a lot of work, and data miners were eager to buy this and produce new products for mostly the pharmaceutical companies, but there are other buyers as well. IOS:  I wanted to get back to another point you mentioned, in that even with anonymized data records of medical records, with all the other information that's out there, you can re-identify or at least limit, perhaps, the pool of people who that data would apply to. What's even more frightening now is that hackers have been stealing health records like crazy over the last couple of years. So, there's a whole dark market of hacked medical data that, I guess, if they got into this IMS database, they would have the keys to the kingdom, in a way. Am I being too paranoid here? AT: Well, no, you correctly point out that there has been a sharp upswing in hacking into medical records. That can happen into a small, individual practice, or it could happen into a large insurance company. And in fact, the largest hacking attack of medical records in the last couple of years has been into Anthem Health, which is the Blue Cross Blue Shield company. Almost 80 million records were hacked in that. So even people that did... I was hacked in that, even though I was not, at the time, a customer of them or had never been a customer of them, but they... One company that I dealt with outsourced to someone else, who outsourced to them. So, all of a sudden, this information can be in circulation. There’s a government website people can look at, and you'll see, every day or two, there are new hackings. Sometimes it involves a few thousand names and an obscure local clinic. Sometimes it'll be a major company, such as a lab test company, and millions of names could be impacted. So, this is something definitely to be concerned about. Yes, you could take these hacked records and match them with anonymized records to try to figure out who people are, but I should point out that there is no recorded instance of hackers getting into these anonymized dossiers by the big data miners. IOS: Right. We hope so! AT: I say recorded or acknowledged instance. IOS: Right. Right. But there's now been sort of an awareness of cyber gangs and cyber terrorism and then the use of, let's say, records for blackmail purposes. I don't want to get too paranoid here, but it seems like there's just a potential for just a lot of bad possibilities. Almost frightening possibilities with all this potential data out there. AT: Well, we have heard recently about rumors of an alleged dossier involving Donald Trump and Russia. IOS: Exactly. AT: And information that... If you think about what kind of information could be most damaging or harmful to someone, it could be financial information. It could be sexual information, or it could be health information. IOS: Yeah, or someone using... or has a prescription to a certain drug of some sort. I'm not suggesting anything, but that... All that information together could have sort of lots of implications, just, you know, political implications, let's say. AT: I mean if you know that someone takes a drug that's commonly used for a mental health problem, that could be information used against someone. It could be used to deny them life insurance. It could be used to deny them a promotion or a job offer. It could be used by rivals in different ways to humiliate people. So, this medical information is quite powerful. One person who has experienced this and spoken publicly about it is the actor, Charlie Sheen. He tested positive for HIV. Others somehow learned of it and blackmailed him. He said he paid millions of dollars to keep that information from going public, before he decided finally that he would stop paying it, and he'd have to tell the world about his medical condition. IOS: Actually I was not aware of the payments he was making. That's just astonishing. So, is there any hope here? Do you see some remedies, through maybe regulations or enforcement of existing laws? Or perhaps we need new laws? AT: As I mentioned, the current rules, HIPAA, allows for the free trade of your data if it's anonymized. Now, I think, given the growth of sophistication in computing, that we should change what the rule is and to define our medical data as any medical information about us, whether or not it's anonymized. So, if a doctor is writing in the electronic health record, you should have a say as to whether or not that information is going to be used elsewhere. A little side point I should mention. There are a lot of good scientists and researchers who want data to see if they can gain insights into disease and new medications. I think people should have the choice whether or not they want to contribute to those efforts. So, you know, there's a lot of good efforts. There's a government effort under way now to gather a million DNA samples from people to make available to science. So, if people want to participate in that, and they think that's good work, they should definitely be encouraged to do so, but I think they should have the say and decide for themselves. And so far, we don't really have that system. So, by redefining what patient data is, to say, "Medical information about a patient, whether or not it's anonymized," I think that would give us the power to do that. IOS: So effectively, you're saying the patient owns the data, is the owner, and then would have to give consent for the data to be used. Is that, about right? AT: I think so. But on the other hand, as I mentioned, I've written this book to encourage this discussion. The problem we have right now is that the trade is so opaque. Companies are extremely reluctant to talk about this commercial trade. So, they do occasionally say that, "Oh, this is great for science and for medicine, and all of these great things will happen." Well, if that is so fantastic, let's have this discussion where everyone will say, "All right. Here's how we use the data. Here's how we share it. Here's how we sell it." Then let people in on it and decide whether they really want that system or not. But it's hard to have that intelligent policy discussion, what's best for the whole country, if industry has decided for itself how to proceed without involving others. IOS: Well, I'm so glad you've written this book. This will, I'm hoping, will promote the discussion that you're talking about. Well, this has been great. I want to thank you for the interview. So, by the way, where can our listeners reach out to you on social media? Do you have a handle on Twitter? Or Facebook? AT: Well, I'm @datacurtain  and I have a webpage, which is http://adamtanner.news/ IOS: Wonderful. Thank you very much, Adam.

John Reites is a veteran from both sides of the startup business world.  He transitioned from "intrapreneur" at Quintiles, where he served as the Head of Digital Health Acceleration, to entrepreneur as the Chief Product Officer and Partner at Thread - a new, innovative digital health company.  Join me today as I talk with John about entrepreneurship in any environment.   00:44 - start 01:13 - From Intrapreneurial to Entrepreneurial 02:07 - Entrepreneur Accountability 03:10 - Paying for Your Own Desserts 04:03 - My Big Quintiles Corporate Experience 06:29 - Skunkworks?! 07:45 - Entrepreneur IN a Large Corporation? 09:49 - Compare and Contrast - Corporate to Startup 11:32 - The End Client is...? 12:29 - For Patients in Studies or the Marketplace? 13:31 - How are They Used Within Studies? 16:18 - The Challenge of Adaptation in Health 18:47 - Role-playing 21:38 - Portable Tech and Spontaneous Reactions 23:26 - App Design Mentality 26:46 - Patients on Call? 29:10 - Finding Clients in the Wild 31:13 - Providing the Information Patients Need 32:50 - On the Horizon 34:11 - Social Media Tip: Mark Traphagen - Compete with Dr. Google Contact John: LinkedIn  |  Twitter THREAD Website  3 ways to engage in remote patient research Connect With Thread:  LinkedIn  |  Twitter  |  Facebook

Mali Phonpadith interviews Myron Radio, a four-time author and President of The R Group. Myron is recognized as an energetic speaker, facilitator, team builder and executive coach. His clients represent a broad range of global Fortune 500 companies, including: PricewaterhouseCoopers, Balfour Beatty, Microsoft, DOW Chemical, ExxonMobil, Constellation Energy, McKesson, Quintiles, ManTech and Northrop Grumman. Federal clients include the Departments Homeland Security, Commerce, and Transportation. He has been widely known for developing and executing successful strategies, revitalizing organizations and delivering impressive bottom-line results. Learn more about Myron here: http://www.the-r-group.com/ Get Myron's Book Dream Makers on Amazon by visiting https://amzn.com/B005Z8VWQS Subscribe to our podcast: https://itunes.apple.com/us/podcast/soar-scn-podcast/id884527835?mt=2 Contact us: www.SOARCommunityNetwork.com

Today in FirstWord:

Jean Paty discusses how to incorporate the patient perspective into clinical development

Globalisation is no longer on the horizon—it’s here, staring us in the face. And for those in leadership roles, understanding its impact is only the first step. Learning how to navigate and think beyond one’s corporate, and geographic, borders is a leadership imperative. Tina Durocher-Murphy, Senior Vice President, Global Human Resources at Quintiles, discusses the importance of overseas experience for HR leaders—even those in large and diverse markets like the US.

Guest: Diane C. Farhi,, MD, Senior Medical Director, Quintiles Laboratories Bio and Contact Info Listen (6:37) Tracking clinical samples around the world Listen (5:34) How to measure sample stability

Tom Pike, Chief Executive Officer of Quintiles speaks on the topic: A Picture of Health: A New Model for Biopharma’s Continued Success

Olga Marchenko from Quintiles gives a brief overview of the upcoming Trends and Innovations in Clinical Trial Statistics Conference to take place April 21-23 in Research Triangle Park, North Carolina.

Eli Lilly and Quintiles entered into a co-investment partnership to develop a new solution using computer-assisted designs that emphasize the improvement of scientific and operational outcomes of clinical trials. The results were shared at the DPharm 2013 event and project leaders from both companies will talk to our host Craig Lipset on how this formation is doing a year later. Also joining Craig is Jeff Lee, CEO, Omniscience to discuss featured news and trends in clinical trial innovation and in particular mobile applications. Host: Craig Lipset, MBA, Head of Clinical Innovation, R&D, Pfizer, Inc. Guests: Jeffrey Kasher, PhD, VP & COO, Eli Lilly & Company Jeff Lee, CEO, Omniscience Mobile Rick Sax, MD, SVP Clinical Design & Reporting Services, Quintiles  

Today in FirstWord:

Negotiating funding for drugs with local health authorities prior to commercialisation is the key to success for biopharmas working in the changing European market, says Quintiles.

Negotiating funding for drugs with local health authorities prior to commercialisation is the key to success for biopharmas working in the changing European market, says Quintiles.

Addressing the drug industry's need to demonstrate value to stakeholders presents a significant opportunity for service providers, according to Jim Featherstone, VP of Quintiles' commercial arm.

Addressing the drug industry's need to demonstrate value to stakeholders presents a significant opportunity for service providers, according to Jim Featherstone, VP of Quintiles' commercial arm.

CRO Quintiles says biomarkers give insight into cancer drug candidates’ efficacy earlier in the development process, reducing trial costs and duration.

CRO Quintiles says biomarkers give insight into cancer drug candidates’ efficacy earlier in the development process, reducing trial costs and duration.

Quintiles’ Jay Norman tells Outsourcing-pharma that data sharing and patient and payer concerns will drive drug industry competition and clinical development decisions accord to new research.

Quintiles’ Jay Norman tells Outsourcing-pharma that data sharing and patient and payer concerns will drive drug industry competition and clinical development decisions accord to new research.

Contract services giant Quintiles has continued its expansion in Africa with a new clinical research services office in Nairobi, Kenya.

Date:3/02/2009Length: 00:012:37Size: 5.77MBThought Leaders: John Doyle Dr.P.H., Managing Director and Practice Leader, Market Access, Quintiles Consulting, and Geoff Garabedian, Managing Director and Practice Leader, Regulatory, Quintiles ConsultingIn this episode, Dr. Doyle outlines cost-based evaluation and market-access strategies based on comparative effectiveness and safety research. Then Mr. Garabedian talks about the impact of regulatory globalization, and finally, there is a discussion covering the latest pharmaceutical initiatives from the European Commission, and how these will impact the global healthcare industry.Play P0dcastFor more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157